<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lorazepam: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lorazepam: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lorazepam: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9573" href="/d/html/9573.html" rel="external">see "Lorazepam: Drug information"</a> and <a class="drug drug_patient" data-topicid="10819" href="/d/html/10819.html" rel="external">see "Lorazepam: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F49334833"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use with opioids (injection, oral):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Abuse, misuse, and addiction (injection, oral):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of benzodiazepines, including lorazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing lorazepam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dependence and withdrawal reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Injection: The continued use of benzodiazepines for several days to weeks may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although lorazepam injection is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of lorazepam injection may precipitate acute withdrawal reactions, which can be life-threatening. For patients using lorazepam injection more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F189926"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ativan;</li>
<li>LORazepam Intensol;</li>
<li>Loreev XR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867397"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-LORazepam;</li>
<li>Ativan;</li>
<li>PMS-LORazepam;</li>
<li>PRO-LORazepam;</li>
<li>TEVA-LORazepam</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1053736"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antianxiety Agent</span>;</li>
<li>
<span class="list-set-name">Antiemetic</span>;</li>
<li>
<span class="list-set-name">Antiseizure Agent, Benzodiazepine</span>;</li>
<li>
<span class="list-set-name">Benzodiazepine</span>;</li>
<li>
<span class="list-set-name">Hypnotic</span>;</li>
<li>
<span class="list-set-name">Sedative</span></li></ul></div>
<div class="block don drugH1Div" id="F53462497"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="492a4678-1bd1-4f7a-9c87-f6e65bb66b16">Iatrogenic benzodiazepine dependency, weaning after prolonged midazolam infusion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iatrogenic benzodiazepine dependency, weaning after prolonged (≥5 days) midazolam infusion:</b> Limited data available; optimal regimen not established. Lorazepam dose and taper schedule must be individualized and will depend upon patient's previous midazolam infusion rate, length of time on benzodiazepines, and severity of withdrawal. Use of Withdrawal Assessment Tool (WAT-1) has been recommended to monitor for iatrogenic withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30234674','lexi-content-ref-22093817']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30234674','lexi-content-ref-22093817'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates: Oral, IV: No standard dose exists; one published approach bases lorazepam dose on current midazolam infusion rate and calculates dose by multiplying the midazolam infusion rate by 0.833; lorazepam doses are administered every 4 hours and once stabilized (ie, WAT-1 score within acceptable range and &lt;2 intermittent doses required) are weaned by 10% to 20% of the original dose every 24 to 48 hours based on patient's risk level for withdrawal; monitor using WAT-1 scale and adjust accordingly; refer to institutional protocol if available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30234674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30234674'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a5b0cb2b-97d8-4c58-b27d-3b3dfbcb0a46">Sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation:</b> Limited data available: Preterm and term neonates: IV: 0.05 to 0.1 mg/kg/dose every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17056842','lexi-content-ref-24675625','lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17056842','lexi-content-ref-24675625','lexi-content-ref-31871244'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90f0e75b-d4ea-42d3-8ff0-2ae4051421da">Seizures, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, acute treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: IV: 0.05 to 0.1 mg/kg/dose administered by slow IV over 1 to 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3752014','lexi-content-ref-1940133','lexi-content-ref-1538303','lexi-content-ref-Sansevere.1','lexi-content-ref-Solanki.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3752014','lexi-content-ref-1940133','lexi-content-ref-1538303','lexi-content-ref-Sansevere.1','lexi-content-ref-Solanki.1'])">Ref</a></span>). In a small study (n=7; weight range: 1.4 to 4.14 kg), lorazepam was administered at a dose of 0.05 mg/kg; if there was no response or only a partial response was seen 15 minutes after the dose, the dose was repeated; up to a total of 3 doses were allowed; maximum total dose: 0.15 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1940133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1940133'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F189951"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7aa0c9e-40a7-4464-a0f9-cd82b8478d81">Chemotherapy-induced nausea and vomiting, anticipatory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, anticipatory:</b> Limited data available: Infants, Children, and Adolescents: Oral: 0.04 to 0.08 mg/kg/dose; maximum dose: 2 mg/dose; administer a dose the night before chemotherapy and again the next day prior to chemotherapy administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24753095']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24753095'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd4ecf6c-77b4-4a40-baff-3d3a51ec5552">Chemotherapy-associated nausea and vomiting, breakthrough</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-associated nausea and vomiting, breakthrough:</b> Limited data available: Children and Adolescents: IV: 0.025 to 0.05 mg/kg/dose every 6 hours as needed; maximum dose: 2 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12956617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12956617'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abd0fdf8-8794-48b5-a9a0-1d9578c73cbe">Anxiety, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety, acute:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;12 years: Limited data available: Oral, IV: Usual: 0.05 mg/kg/dose (maximum dose: 2 mg/dose) every 4 to 8 hours; range: 0.02 to 0.1 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 0.25 to 2 mg/dose 2 or 3 times daily; maximum dose: 2 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.2011'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b51ef66-a744-486c-9bf3-12824ec3d8ed">Sedation; procedural</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation; procedural:</b> Limited data available: Children and Adolescents: Oral: Usual: 0.05 mg/kg; range reported in literature: 0.02 to 0.09 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6132612','lexi-content-ref-1934919','lexi-content-ref-6109421','lexi-content-ref-6123337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6132612','lexi-content-ref-1934919','lexi-content-ref-6109421','lexi-content-ref-6123337'])">Ref</a></span>). <b>Note:</b> In adults, the maximum dose is 4 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infants, Children, and Adolescents: 0.1 mg/kg slow IV; may repeat dose once in 5 to 10 minutes; maximum dose: 4 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: <b>Note:</b> Lorazepam is not the preferred agent for intranasal administration, guidelines recommend midazolam as the preferred agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: 0.1 mg/kg/dose; maximum dose: 5 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16698412','lexi-content-ref-21275979','lexi-content-ref-Kliegman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16698412','lexi-content-ref-21275979','lexi-content-ref-Kliegman.2020'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128487"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Children ≥12 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, some clinicians recommend no dosage adjustments are necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">IV: No dosage adjustment necessary for acute doses; use repeated doses with caution; may increase the risk of propylene glycol toxicity. Monitor closely if using for prolonged periods of time or at high doses. In adults, the osmolar gap has been shown to be a surrogate marker for propylene glycol accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-18657015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-18657015'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51128488"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: No dosage adjustment necessary. For severe hepatic disease, use with caution; benzodiazepines may worsen hepatic encephalopathy.</p></div>
<div class="block doa drugH1Div" id="F189931"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9573" href="/d/html/9573.html" rel="external">see "Lorazepam: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Reduce dose or avoid use in patients receiving opioids or with significant chronic disease (eg, respiratory compromise). Avoid use in patients with a history of substance use, misuse of medications, or depression, except for acute or emergency situations (eg, acute agitation, status epilepticus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-Craske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-Craske.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34cc2c7c-f48e-43c2-99c1-d056a74ca772">Akathisia, antipsychotic-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Akathisia, antipsychotic-induced (alternative agent) (off-label use):</b>
<b>Oral (immediate release):</b> Initial: 0.5 to 1 mg twice daily; may increase dose based on response and tolerability up to 6 mg/day, in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2860136','lexi-content-ref-2884681','lexi-content-ref-Lavonas.1','lexi-content-ref-Stroup.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2860136','lexi-content-ref-2884681','lexi-content-ref-Lavonas.1','lexi-content-ref-Stroup.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="681d778e-2c1e-46c3-9264-d477867f0a71">Anxiety</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Anxiety and agitation, acute/severe (monotherapy or adjunctive therapy): IM, IV, Oral (immediate release):</b> 0.5 to 2 mg every 4 to 6 hours as needed up to 10 mg/day; adjust dose based on response and tolerability. In severely agitated inpatients, some experts recommend doses up to 4 mg and repeat IM or IV doses as frequently as 10 to 30 minutes; may give alone or in combination with an antipsychotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moore.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moore.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Anxiety disorders (adjunctive therapy or monotherapy) (alternative agent): Note:</b> Generally used short-term for symptom relief until preferred therapy (eg, serotonin reuptake inhibitor) is effective (eg, 4 to 6 weeks followed by tapering). Long-term low-dose (eg, 0.5 mg/day) therapy may be considered in select patients, when preferred treatments are ineffective or poorly tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-25081580','lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-25081580','lexi-content-ref-35900161'])">Ref</a></span>). Use with caution in patients with comorbid posttraumatic stress disorder (PTSD); benzodiazepines may worsen PTSD symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-VADOD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-VADOD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i>
<b>Oral:</b> Initial: 0.5 to 1 mg 2 to 3 times daily; although most patients will experience relief with this dose, may increase daily dose gradually based on response and tolerability in increments of 1 mg every 2 to 3 days up to 6 mg/day in 2 to 4 divided doses; some patients may require doses up to 10 mg/day for optimal response. Some experts recommend a lower initial dose of 0.5 to 1 mg once to twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release 24-hour capsules: </i>
<b>Oral: </b>Initial: Determine stable daily dose using IR tablets in 3 divided doses. Maintenance: May convert to extended release at the total daily dose of immediate release; administer once daily in the morning. <b>Note:</b> For dosage adjustments, discontinue extended release and switch to immediate release.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Advanced cancer and/or palliative care: IM, IV, Oral (immediate release):</b> 0.25 to 2 mg every 3 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Irwin.2019','lexi-content-ref-Roy-Byrne.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Irwin.2019','lexi-content-ref-Roy-Byrne.2019'])">Ref</a></span>). <b>Note:</b> The injectable solution may be administered rectally or subcutaneously, and the tablet and oral solution may be administered sublingually at the same doses when other routes are unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6132630','lexi-content-ref-3427562','lexi-content-ref-6121043','lexi-content-ref-Harman.2019','lexi-content-ref-24681184','lexi-content-ref-vonGunten.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6132630','lexi-content-ref-3427562','lexi-content-ref-6121043','lexi-content-ref-Harman.2019','lexi-content-ref-24681184','lexi-content-ref-vonGunten.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Performance- or phobia-related anxiety (monotherapy or adjunctive therapy)</b>: <b>Note</b>: Provide a test dose, at the same dose to be used for treatment, in advance of the stimulus to ensure tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (immediate release):</b> 0.5 to 2 mg once 30 to 60 minutes before the stimulus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.2019','lexi-content-ref-Swinson.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.2019','lexi-content-ref-Swinson.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Procedural anxiety (premedication):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (immediate release), Sublingual</b> (off-label use): 0.5 to 2 mg once 30 to 90 minutes before procedure; if needed due to incomplete response, may repeat the dose (usually at 50% of the initial dose) after 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26185424','lexi-content-ref-Choy.2019','lexi-content-ref-6144317','lexi-content-ref-Shih.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26185424','lexi-content-ref-Choy.2019','lexi-content-ref-6144317','lexi-content-ref-Shih.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 to 4 mg <b>or</b> 0.02 to 0.04 mg/kg (maximum single dose: 4 mg) once 5 to 20 minutes before procedure; if needed based on incomplete response and/or duration of procedure, may repeat the dose (usually at 50% of the initial dose) after ≥5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Choy.2019','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Choy.2019','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09182ccc-736f-4977-bd41-111849a8fa38">Catatonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catatonia (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diagnosis: </i>
<b>Note:</b> Partial, temporary relief of signs following administration is consistent with the diagnosis; a negative response does not rule out catatonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Coffey.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Coffey.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b> (preferred): 1 to 2 mg once; if no response in 5 to 10 minutes, repeat dose once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Coffey.2019','lexi-content-ref-19884605','lexi-content-ref-19969591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Coffey.2019','lexi-content-ref-19884605','lexi-content-ref-19969591'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, Oral (immediate release), Sublingual:</b> 2 mg once; may administer up to 2 additional doses at 3-hour intervals if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Coffey.2019','lexi-content-ref-19969591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Coffey.2019','lexi-content-ref-19969591'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i>
<b>Note:</b> For patients with malignant catatonia, electroconvulsive therapy should begin immediately (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22834451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22834451'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV, Oral (immediate release):</b> Initial: 1 to 2 mg 3 times daily; IV preferred for initial dosing with switch to oral as patient improves. May increase dose based on response and tolerability in increments of 3 mg every 1 to 2 days to a usual dose of 6 to 21 mg/day. Doses up to 30 mg/day have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Coffey.2019.1','lexi-content-ref-19996245','lexi-content-ref-19884605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Coffey.2019.1','lexi-content-ref-19996245','lexi-content-ref-19884605'])">Ref</a></span>). For patients at risk of cardiorespiratory compromise or oversedation, some experts recommend initiating with 0.5 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Coffey.2019.1','lexi-content-ref-22834451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Coffey.2019.1','lexi-content-ref-22834451'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of treatment:</i> Remission is usually achieved in 4 to 10 days; maintenance therapy at the effective dose is usually continued for 3 to 6 months to maintain recovery, although longer courses may be needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Coffey.2019.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Coffey.2019.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1e05362e-7b8e-4954-8b24-f98400ae8593">Chemotherapy-induced nausea and vomiting, prevention and treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, prevention and treatment (adjunctive therapy) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Anticipatory or breakthrough nausea/vomiting, as an adjunct to conventional antiemetics:</i>
<b>Oral (immediate release), IV, Sublingual:</b> 0.5 to 1 mg every 6 hours as needed; doses up to 2 mg have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18391612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18391612'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d93e0d56-b2c1-4c09-9d4b-fabe64541e4d">Intoxication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intoxication: Cocaine, methamphetamine, and other sympathomimetics (off-label use): </b>Based on limited data: <b>IV:</b> 2 to 4 mg every 3 to 10 minutes as needed for agitation, sedation, seizures, hypertension, and tachycardia until desired symptom control achieved. Large cumulative doses may be required for some patients; monitor for respiratory depression and hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.2019','lexi-content-ref-Boyer.2019b','lexi-content-ref-Nelson.2019','lexi-content-ref-28297728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.2019','lexi-content-ref-Boyer.2019b','lexi-content-ref-Nelson.2019','lexi-content-ref-28297728'])">Ref</a></span>). <b>Note: </b>Initiating treatment at 1 mg may be adequate in patients who are only mildly or moderately intoxicated, but doses should be repeated or increased as needed. Consider IM administration if IV access is not possible; however, effects will be delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6abb6df-ed17-4db8-adf7-fad1b498ff10">Mechanically ventilated patients in the ICU, sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mechanically ventilated patients in the ICU, sedation (alternative agent) (off-label use):</b>
<b>Note:</b> Used as part of a multimodal strategy. In general, nonbenzodiazepine sedation is preferred due to risk of prolonged sedation and delirium with continuous benzodiazepine use. Titrate to light level of sedation (eg, Richmond Agitation-Sedation Scale 0 to −2) or clinical effect (eg, ventilator dyssynchrony). Intermittent as-needed therapy is preferred to avoid drug accumulation and prolonged sedation associated with continuous infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>). Continuous infusions are not recommended for use in most ICU patients due to propylene glycol (PG) accumulation and subsequent complications (osmol gap metabolic acidosis, kidney failure); monitor PG accumulation with osmol gap; nonbenzodiazepine or midazolam continuous infusions are generally preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-18657015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-18657015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent (preferred): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Non–weight-based dosing: <b>IV:</b> Initial dose: 1 to 4 mg; Maintenance: 1 to 4 mg every 2 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16540958','lexi-content-ref-Tietze.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16540958','lexi-content-ref-Tietze.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dosing: <b>IV:</b> Initial dose: 0.02 to 0.04 mg/kg (maximum single dose: 4 mg); Maintenance: 0.02 to 0.06 mg/kg every 2 to 6 hours as needed (maximum single dose: 4 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16540958','lexi-content-ref-8605792','lexi-content-ref-18949456','lexi-content-ref-23269131','lexi-content-ref-Tietze.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16540958','lexi-content-ref-8605792','lexi-content-ref-18949456','lexi-content-ref-23269131','lexi-content-ref-Tietze.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous infusion:</i>
<b> IV:</b> 0.5 to 10 mg/hour <b>or </b>0.01 to 0.1 mg/kg/hour continuous infusion (maximum dose: 10 mg/hour) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18949456','lexi-content-ref-23269131','lexi-content-ref-Tietze.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18949456','lexi-content-ref-23269131','lexi-content-ref-Tietze.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb3c9c3d-af3b-4e18-902e-e0c1117bc1a7">Neuroleptic malignant syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroleptic malignant syndrome (adjunctive therapy) (off-label use)</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Following withdrawal of causative agent while continuing supportive care, use for moderate to severe muscle rigidity with elevated creatine kinase. May also use for any patient experiencing agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wijdicks.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wijdicks.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 0.5 to 2 mg every 4 to 6 hours until symptom resolution; use higher doses (eg, 1 to 2 mg) for management of muscle rigidity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wijdicks.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wijdicks.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bdc9ea7-289f-4752-8056-e3eef3f779c9">Seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures: Note:</b> If IV access is not available, IM lorazepam is not recommended due to erratic absorption and a slow time to peak drug levels. May consider sublingual or subcutaneous lorazepam or IM midazolam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drappatz.2019','lexi-content-ref-Harman.2019','lexi-content-ref-26071998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drappatz.2019','lexi-content-ref-Harman.2019','lexi-content-ref-26071998'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute active seizures (non-status epilepticus) (off-label use): IV:</b> 4 mg given at a maximum rate of 2 mg/minute; may repeat at 3 to 5 minutes if seizures continue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.2019','lexi-content-ref-25583219','lexi-content-ref-OConnor.2019','lexi-content-ref-Schachter.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.2019','lexi-content-ref-25583219','lexi-content-ref-OConnor.2019','lexi-content-ref-Schachter.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Status epilepticus:</b>
<b>IV:</b> 4 mg given at a maximum rate of 2 mg/minute; may repeat at 3 to 5 minutes if seizures continue; a nonbenzodiazepine antiseizure agent should follow to prevent seizure recurrence, even if seizures have ceased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.2019','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.2019','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bce45f2d-590a-4d58-a2ee-8620e421f49b">Serotonin syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome (serotonin toxicity) (off-label use):</b>
<b>IV:</b> 2 to 4 mg IV every 8 to 10 minutes based upon patient response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Boyer.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Boyer.2019a'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5aaf2b38-7731-4c1e-a1d0-efefaf9b21a5">Substance withdrawal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Substance withdrawal: </b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Alcohol withdrawal syndrome (alternative agent) <b>(off-label use)</b>: Note: </b>Withdrawal will progress at different rates in some patients; flexibility in dosing and duration is warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoffman.2019','lexi-content-ref-VADOD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoffman.2019','lexi-content-ref-VADOD.2'])">Ref</a></span>). Regimens vary and depend on withdrawal history, degree of current withdrawal symptoms, blood alcohol concentration, and whether the patient is treated inpatient or in the ambulatory setting. Many facilities only treat alcohol withdrawal in the ambulatory setting if Clinical Institute Withdrawal Assessment for Alcohol, revised scale (CIWA-Ar) score is ≤15 and there is no history of withdrawal seizures or delirium tremens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1','lexi-content-ref-33224688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1','lexi-content-ref-33224688'])">Ref</a></span>). Although longer-acting benzodiazepines are preferred in general, shorter-acting benzodiazepines, including lorazepam, may be preferable in patients with impaired liver function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoffman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoffman.2019'])">Ref</a></span>). The following are 2 suggested regimens.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Symptom-triggered regimen:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Some experts recommend symptom-triggered regimens for patients with CIWA-Ar &gt;15 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoffman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoffman.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral (immediate release), IV:</b> 2 to 4 mg as needed per institution-specific protocol until appropriate sedation achieved; dose and frequency determined by withdrawal symptom severity using a validated severity-assessment scale such as the CIWA-Ar (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoffman.2019','lexi-content-ref-24407777','lexi-content-ref-28006997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoffman.2019','lexi-content-ref-24407777','lexi-content-ref-28006997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fixed-dose regimen: </i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Some experts recommend fixed-dose regimens for patients at risk for mild withdrawal (CIWA-Ar ≤15), particularly in an ambulatory setting where CIWA-Ar scores cannot be reliably administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1'])">Ref</a></span>). Hold doses for excessive sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoffman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoffman.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Days 1 through 3: <b>Oral (immediate release), IV</b>
<b>: </b>2 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19485969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19485969'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Day 4: <b>Oral (immediate release), IV: </b>2 mg twice daily, then discontinue lorazepam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19485969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19485969'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Breakthrough symptoms: <b>Oral (immediate release), IV:</b> May administer additional 1 or 2 mg doses as needed to treat breakthrough symptoms throughout the taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19485969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19485969'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Opioid withdrawal (autonomic instability and agitation) (adjunctive therapy) (alternative agent)</b>
<b>(off-label use)</b>
<b>:</b> Based on limited data: <b>IV:</b> 1 to 2 mg every 10 minutes until hemodynamically stable and adequate sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29325983','lexi-content-ref-Stolbach.2019','lexi-content-ref-29605483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29325983','lexi-content-ref-Stolbach.2019','lexi-content-ref-29605483'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0cafbc8a-abd9-42c0-9a5e-50ae32938929">Vertigo, acute episodes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vertigo, acute episodes (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve use for symptomatic relief of episodes lasting several hours to days (maximum duration: 3 days); chronic use may impede adaptation and recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV, Oral (immediate release):</b> 0.5 to 2 mg every 4 to 12 hours as needed for up to 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32267799','lexi-content-ref-Furman.2019','lexi-content-ref-12521357','lexi-content-ref-15791890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32267799','lexi-content-ref-Furman.2019','lexi-content-ref-12521357','lexi-content-ref-15791890'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy: </b>Unless safety concerns require a more rapid withdrawal, gradually taper to detect reemerging symptoms and minimize rebound and withdrawal symptoms in patients receiving therapy ≥4 weeks or as appropriate based on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VADOD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VADOD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Low or moderate dose, no concerns for benzodiazepine use disorder:</b> Taper total daily dose by 20% to 25% every week based on response and tolerability (taper increments will be limited by available dosage forms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-VADOD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-VADOD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended or high-dose therapy, or suspected benzodiazepine use disorder:</b> Taper total daily dose by approximately 25% every 1 to 2 weeks based on response, tolerability, and individual patient factors (taper increments will be limited by available dosage forms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-VADOD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-VADOD.2'])">Ref</a></span>). Reduce dose more rapidly in the beginning, and slow the dose reduction as the taper progresses because earlier stages of withdrawal are easier to tolerate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VADOD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VADOD.2'])">Ref</a></span>). The optimal duration and taper increment will vary; up to 6 months may be necessary for some patients on higher doses, and a taper rate of 50% every week may be tolerated in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-VADOD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-VADOD.2'])">Ref</a></span>). For benzodiazepines with half-lives significantly &lt;24 hours, including lorazepam, consider substituting an equivalent dose of a long-acting benzodiazepine to allow for a more gradual reduction in drug serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VADOD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VADOD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991780"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6713774','lexi-content-ref-22216526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6713774','lexi-content-ref-22216526'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Parenteral:</b> No dosage adjustment necessary for acute doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6713774','lexi-content-ref-22216526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6713774','lexi-content-ref-22216526'])">Ref</a></span>); use repeated doses with caution; may increase the risk of propylene glycol toxicity. Monitor osmol gap closely as a surrogate marker for propylene glycol accumulation, especially if using for prolonged periods of time or at high doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-18657015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-18657015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6713774','lexi-content-ref-22216526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6713774','lexi-content-ref-22216526'])">Ref</a></span>): <b>Oral, Parenteral:</b> No supplemental dose or dosage adjustment necessary; use repeated parenteral doses with caution; monitor osmol gap closely as a surrogate marker for propylene glycol accumulation, especially if using for prolonged periods of time or at high doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): <b>Oral, Parenteral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use repeated parenteral doses with caution; monitor osmol gap closely as a surrogate marker for propylene glycol accumulation, especially if using for prolonged periods of time or at high doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15685515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15685515'])">Ref</a></span>): <b>Oral, Parenteral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use repeated intravenous doses with caution; monitor osmol gap closely as a surrogate marker for propylene glycol accumulation, especially if using for prolonged periods of time or at high doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Unlikely to be dialyzed (highly protein bound): <b>Oral, Parenteral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use repeated parenteral doses with caution; monitor osmol gap closely as a surrogate marker for propylene glycol accumulation, especially if using for prolonged periods of time or at high doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988938"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The hepatic dosing recommendations are based up on the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Lorazepam metabolism is not altered in patients with cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15924505','lexi-content-ref-26322116','lexi-content-ref-28871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15924505','lexi-content-ref-26322116','lexi-content-ref-28871'])">Ref</a></span>); however, the elimination half-life is prolonged due to increased volume of distribution secondary to decreased protein binding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28871'])">Ref</a></span>). First time hepatic encephalopathy events may be precipitated by benzodiazepine use in benzodiazepine-naive patients with cirrhosis; occurrence was observed primarily between 3 to 10 days of benzodiazepine use in one study, potentially due to drug accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29774154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29774154'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial or dose titration in patients with preexisting liver cirrhosis: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Parenteral: Note: </b>Avoid use or use with caution in patients with known hepatic encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Child-Turcotte-Pugh class A:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Intermittent dosing:</i> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Continuous infusion:</i> Use should generally be avoided and only if benefits outweigh the risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Child-Turcotte-Pugh class B and C:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Intermittent dosing:</i> No dosage adjustment necessary; however, extending the dosing interval (eg, increasing from every 6 hours to every 12 hours) should be considered when prolonged (&gt;3 days) use is anticipated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Continuous infusion:</i> Use should generally be avoided and only if benefits outweigh the risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: Note: </b>ER formulation should not be used in patients with hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Child-Turcotte-Pugh class A: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Child-Turcotte-Pugh class B and C:</b>
<b>Note:</b> Use of a shorter acting benzodiazepine (eg, oxazepam) should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial:</i> Reduce to at least 50% of usual recommended dose and extend dosing interval (eg, if the usual dosing interval is every 6 hours, then extend to every 12 hours) to avoid lorazepam accumulation; gradually titrate based on response and tolerability to the lowest effective dose and frequency. For patients experiencing new onset hepatic encephalopathy, consider dose taper to discontinuation. Avoid use or use with caution in patients with known hepatic encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F55709517"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anterograde amnesia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Benzodiazepines, including lorazepam, can impair explicit memory and produce short-term <b>anterograde amnesia</b> (ie, memory of information or events after drug administration). Retrograde amnesia (ie, events or information prior to drug administration) is unaffected. However, the magnitude of the amnesic effect from benzodiazepines differs among the various agents, depending on their pharmacokinetic/pharmacodynamic properties, route of administration, and dose. Anterograde amnesia is associated with higher doses, IV administration, and benzodiazepines with faster absorption and higher potency. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11307041','lexi-content-ref-1684055','lexi-content-ref-20138190','lexi-content-ref-1357612','lexi-content-ref-10519733','lexi-content-ref-2905804','lexi-content-ref-3698460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11307041','lexi-content-ref-1684055','lexi-content-ref-20138190','lexi-content-ref-1357612','lexi-content-ref-10519733','lexi-content-ref-2905804','lexi-content-ref-3698460'])">Ref</a></span>). Lorazepam has also been reported to produce an atypical effect on implicit memory, disrupt performance on explicit memory tasks, and impair focused attention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20138190','lexi-content-ref-10519733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20138190','lexi-content-ref-10519733'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i> Dose-related. Benzodiazepines, including lorazepam, bind to the gamma-aminobutyric acid (GABA)-A receptor, subsequently increasing the frequency of chloride channel opening and producing GABA’s inhibitory effect throughout the CNS. The GABA-A receptor complex is composed of five subunits, each with multiple isoforms. Each receptor complex contains a benzodiazepine-binding site, which is classified into several types, based on the alpha subunit isoforms and clinical effects related to each type. The BZ1 receptor type, containing the alfa1 subunit isoform, is highly concentrated in the cortex, thalamus, and cerebellum, and is responsible for benzodiazepine-associated anterograde amnesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23789008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23789008'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid</p>
<p style="text-indent:-2em;margin-left:6em;">IV administration<b>: </b>Following a single dose of IV lorazepam, a delayed onset of amnesic action of 15 to 30 minutes has been observed, with a duration between 4 to 8 hours. The onset latency is also dose-related, with shorter onset for higher lorazepam doses (ie, 15 minutes after 4 mg) and a longer onset for lower doses (ie, 30 minutes after 2 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2905804','lexi-content-ref-9845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2905804','lexi-content-ref-9845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Specific benzodiazepine: Benzodiazepines, such as lorazepam, with a short half-life, rapid onset, and administered IV versus oral, are associated with a high propensity for amnesic effects. However, midazolam is considered to have superior amnestic properties when compared to lorazepam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15829394','lexi-content-ref-11307041','lexi-content-ref-15078112','lexi-content-ref-2905804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15829394','lexi-content-ref-11307041','lexi-content-ref-15078112','lexi-content-ref-2905804'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23789008','lexi-content-ref-6151849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23789008','lexi-content-ref-6151849'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lorazepam can cause significant <b>drowsiness</b> and <b>sedated state; </b>patients also report having "slowed down thinking" (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11307041','lexi-content-ref-3698460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11307041','lexi-content-ref-3698460'])">Ref</a></span>). In addition, lorazepam has been shown to cause psychomotor impairment by increasing reaction time and decreasing reaction accuracy. Benzodiazepines, in general, are associated with an increased risk of motor vehicle accidents and falls (particularly in older adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18570226','lexi-content-ref-28539164','lexi-content-ref-32536331','lexi-content-ref-15762814','lexi-content-ref-11314681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18570226','lexi-content-ref-28539164','lexi-content-ref-32536331','lexi-content-ref-15762814','lexi-content-ref-11314681'])">Ref</a></span>). Tolerance usually develops to the sedative effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22536226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22536226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3698460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3698460'])">Ref</a></span>); benzodiazepines, including lorazepam, bind to the gamma-aminobutyric acid (GABA)-A receptor, subsequently increasing the frequency of chloride channel opening and producing GABA’s inhibitory effect throughout the CNS. Benzodiazepine-associated sedation are mediated by the alpha 1-containing GABA-A receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3427562','lexi-content-ref-21353710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3427562','lexi-content-ref-21353710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>IV administration: Sedative effects: Due to relatively low lipid solubility, onset of sedation is delayed at 15 to 20 minutes, and may require up to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23269131','lexi-content-ref-22428972','lexi-content-ref-15121142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23269131','lexi-content-ref-22428972','lexi-content-ref-15121142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Oral administration: Sedative effects: 20 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15121142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15121142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (cognitive effects) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22298396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22298396'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Route of administration (IV administration is associated with a higher risk of sedation versus oral)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurodevelopmental effects in children</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Animal studies have shown that prolonged or repeated exposure to medications for anesthesia or sedation cause adverse effects on brain maturation resulting in changes in behavior and learning. Some human studies have also suggested similar effects, including epidemiological studies in humans that have observed various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and attention deficit hyperactivity disorder. However, data are limited, inconclusive, and further studies are needed to fully characterize findings. Based on the potential risk, the FDA warned in 2016 that in neonates, children &lt;3 years, or patients in the third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis) undergoing repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures/critical illness, there may be detrimental effects on the child's or fetus’ brain development which may lead to various cognitive and behavioral problems. Relatively short exposure (&lt;3 hours) to sedatives or anesthetics during surgery or procedures is unlikely to adversely affect brain development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2016','lexi-content-ref-30921252','lexi-content-ref-33509654','lexi-content-ref-28915132','lexi-content-ref-21507125','lexi-content-ref-9872743','lexi-content-ref-32426747','lexi-content-ref-23413121','lexi-content-ref-SPS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2016','lexi-content-ref-30921252','lexi-content-ref-33509654','lexi-content-ref-28915132','lexi-content-ref-21507125','lexi-content-ref-9872743','lexi-content-ref-32426747','lexi-content-ref-23413121','lexi-content-ref-SPS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; in juvenile animal studies, drugs that potentiate gamma-aminobutyric acid activity and/or block N-methyl-D aspartate receptors for &gt;3 hours demonstrated widespread neuronal and oligodendrocyte cell loss along with alteration in synaptic morphology and neurogenesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Neonates, children &lt;3 years, or pregnant patients during their third trimester undergoing procedures lasting &gt;3 hours or multiple procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2016'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Paradoxical reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paradoxical reactions</b>, sometimes referred to as disinhibitory reactions or behavioral disinhibition, have been reported in children, adults, and older adults with benzodiazepine use, particularly in those with risk factors. Reactions are relatively uncommon and have been characterized in a number of ways, including increased talkativeness, excitement, restlessness, hyperactivity, sleep disturbances<b>,</b> hostility, rage, agitation, and/or <b>aggressive behavior</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3137624','lexi-content-ref-12186578','lexi-content-ref-1677237','lexi-content-ref-15460178','lexi-content-ref-15961964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3137624','lexi-content-ref-12186578','lexi-content-ref-1677237','lexi-content-ref-15460178','lexi-content-ref-15961964'])">Ref</a></span>). In children, paradoxical reactions to benzodiazepines, particularly midazolam, have been most commonly described as agitation, restlessness, inconsolable crying, screaming, disorientation, and/or excitement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (potentially, although may also be idiosyncratic); exact mechanism is unclear due to limited evidence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3137624','lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3137624','lexi-content-ref-15460178'])">Ref</a></span>). One hypothesis has suggested that increased GABAergic activity in the brain from benzodiazepines causes a decrease in the restraining influence of the frontal cortex, thereby causing excitement, hostility, and rage. An additional proposed mechanism is that benzodiazepines can reduce serotonergic neurotransmission, subsequently causing aggressive behavior. Another mechanism is that in select patients with genetic variations in GABA-A receptors, there is decreased GABA transmission with benzodiazepines which results in neuronal overexcitation manifested clinically as a paradoxical reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; in case reports involving lorazepam, paradoxical reactions occurred within several hours to 24 hours after the first dose; reactions subsided within 24 to 48 hours of discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15198','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15198','lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Benzodiazepines, in general:</p>
<p style="text-indent:-2em;margin-left:8em;">Age related (extremes of age):</p>
<p style="text-indent:-2em;margin-left:10em;">• Children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178','lexi-content-ref-10519733','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178','lexi-content-ref-10519733','lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Disease or condition related:</p>
<p style="text-indent:-2em;margin-left:10em;">• Past history of aggressive behavior or violence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Alcoholism or history of alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Psychiatric or personality disorders, including affective disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178','lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Patient related:</p>
<p style="text-indent:-2em;margin-left:10em;">• Genetic predisposition (potential risk factor) (ie, variability in the density of the GABA-benzodiazepine receptors throughout the brain, a persistence of a juvenile pattern of benzodiazepine response in adulthood, or multiple allelic forms of the receptors with varying affinities for benzodiazepines have all been suggested as potentially playing a role) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178','lexi-content-ref-29723722','lexi-content-ref-3661967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178','lexi-content-ref-29723722','lexi-content-ref-3661967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Other potential risk factors: <b>Note</b>: Not established risk factors since evidence is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12186578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12186578'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Higher doses (likely a risk, but not firmly established) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3137624','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3137624','lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Parenteral benzodiazepine administration (potential risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Specific benzodiazepines (potential risk): Benzodiazepines with a short half-life and/or those considered to have higher potency (eg, alprazolam, clonazepam, lorazepam, triazolam) compared to lower potency benzodiazepines are believed to increase the risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3137624','lexi-content-ref-12186578','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3137624','lexi-content-ref-12186578','lexi-content-ref-29723722'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Propylene glycol toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Propylene glycol, a solvent used in many pharmaceutical preparations, is found in parenteral lorazepam. High doses, continuous use, and/or prolonged use of IV lorazepam can cause propylene glycol accumulation and subsequent toxicity in adults and children, especially low birth-weight infants and those with hepatic or kidney insufficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25762872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25762872'])">Ref</a></span>). Propylene glycol accumulation and toxicity is primarily manifested as hyperosmolar metabolic acidosis (ie, a high anion gap metabolic acidosis with elevated osmol gap) and toxicity is associated with acute kidney injury, intravascular hemolysis, hypotension, cardiac arrhythmias, seizures, mental status changes, and CNS depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-19920159','lexi-content-ref-16159998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-19920159','lexi-content-ref-16159998'])">Ref</a></span>). The osmol gap is correlated with serum propylene glycol concentrations and can be used as a surrogate marker to monitor for propylene glycol accumulation and potential toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-14524641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-14524641'])">Ref</a></span>). Pediatric patients do accumulate propylene glycol but less often display laboratory abnormalities compared to adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12483068','lexi-content-ref-26472950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12483068','lexi-content-ref-26472950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; propylene glycol is oxidized by alcohol dehydrogenase to lactaldehyde, which is metabolized by aldehyde dehydrogenase to lactic acid. The accumulation of lactic acid results in metabolic acidosis, but is usually well tolerated. Lactate in this scenario is not generated from any underlying pathology. The lactate is oxidized to pyruvate and then is metabolized by the normal carbohydrate processes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; propylene glycol accumulation, as evidenced by a hyperosmolar anion gap metabolic acidosis, has been observed as early as 48 hours following high-dose continuous infusions (mean lorazepam dose: 8.1 mg/kg; mean infusion rate: 0.16 mg/kg/hour) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Duration: Continuous infusions &gt;48 hours in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286548','lexi-content-ref-18543419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286548','lexi-content-ref-18543419'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Dose:</p>
<p style="text-indent:-2em;margin-left:8em;">- Neonates: Large amounts of propylene glycol orally, IV (eg, &gt;3,000 mg/day), or topically (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9024461','lexi-content-ref-19188870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9024461','lexi-content-ref-19188870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Adult: High continuous doses of IV lorazepam (doses exceeding recommended adult dosage range of 0.1 mg/kg/hour in critically ill patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286548','lexi-content-ref-18543419','lexi-content-ref-18657015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286548','lexi-content-ref-18543419','lexi-content-ref-18657015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney dysfunction (propylene glycol is excreted unchanged in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19920159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19920159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hepatic dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19920159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19920159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant medications also containing propylene glycol (eg, diazepam, esmolol, nitroglycerin, phenytoin, phenobarbital, sulfamethoxazole/trimethoprim) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27124045','lexi-content-ref-10991709','lexi-content-ref-14524641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27124045','lexi-content-ref-10991709','lexi-content-ref-14524641'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired alcohol dehydrogenase enzyme system (eg, young children) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19920159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19920159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant disulfiram or metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19920159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19920159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19920159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19920159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19920159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19920159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Propylene glycol concentrations exceeding 25 mg/dL. <b>Note</b>: Serum propylene glycol concentrations are difficult to obtain in most clinical settings and test turnaround time is slow; osmol gap is recommended as a surrogate marker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286548','lexi-content-ref-26472950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286548','lexi-content-ref-26472950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• In the absence of other osmotic agents (eg, alcohols), an osmol gap of ≥10 was predictive of elevated propylene glycol concentrations; values of ≥12 suggest propylene glycol toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-26472950','lexi-content-ref-18657015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286548','lexi-content-ref-16422667','lexi-content-ref-26472950','lexi-content-ref-18657015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Critically ill neonates, especially those weighing &lt;5 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472950'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Therapeutic use of benzodiazepines, including lorazepam, is associated with a <b>withdrawal syndrome </b>in children and adults<b>, </b>particularly following abrupt or overly rapid discontinuation. Benzodiazepine-associated withdrawal symptoms can include new withdrawal symptoms or rebound symptoms, both of which are typically transient, short-lasting, and reversible. A persistent post-withdrawal disorder, which can be long-lasting, severe, and potentially irreversible, has also been described. In general, withdrawal symptoms are typically mild and characterized as anxiety, panic attacks, restlessness, insomnia and other sleep disturbances, irritability, poor concentration, confusion, nausea/vomiting, weight loss, tremor, diaphoresis, tachycardia, and muscle pain/stiffness. Severe symptoms such as seizure and psychosis may also rarely occur following abrupt discontinuation. Severe withdrawal may be fatal. Data are limited on persistent post-withdrawal disorders, but cognitive impairment, depression, anxiety, sensory disturbances (eg, tinnitus, paresthesia, skin sensations), motor disturbances (eg, muscle pain, weakness, spasms), and GI disturbances have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3092053','lexi-content-ref-15078112','lexi-content-ref-32259826','lexi-content-ref-16720707','lexi-content-ref-4041699','lexi-content-ref-6120058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3092053','lexi-content-ref-15078112','lexi-content-ref-32259826','lexi-content-ref-16720707','lexi-content-ref-4041699','lexi-content-ref-6120058'])">Ref</a></span>). There are also rare case reports of new-onset mania occurring after abrupt withdrawal of chronic lorazepam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2525581']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2525581'])">Ref</a></span>). Severity, onset, and duration of any benzodiazepine withdrawal syndrome varies based on several factors, such as specific benzodiazepine administered (and its half -life), dose, and duration of use. However, in general, new withdrawal symptoms typically resolve within 2 to 4 weeks and rebound symptoms may last 3 weeks, but persistent post-withdrawal symptoms may last &gt;6 weeks and take 6 to 12 months to completely resolve, and in some cases, persist for years. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112','lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112','lexi-content-ref-32259826'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Withdrawal; exact mechanisms are complex and unclear, but chronic exposure to benzodiazepines alters GABAergic neurotransmission (up/down regulation of gamma-aminobutyric acid [GABA]-A receptor subunits) and rapid or abrupt withdrawal results in underactivity of inhibitory GABA functions subsequently increasing excitatory nervous activity and likely contributing to symptoms associated with withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19900604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19900604'])">Ref</a></span>). A role of glutamate receptors, including N-methyl-D aspartate (NMDA)-, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-receptors, and metabotropic glutamate (mGlu) receptors, has also been suggested. In mice and rat studies, antagonists for glutamate receptors have shown the ability to potently suppress the withdrawal signs caused by chronic benzodiazepine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12725868','lexi-content-ref-10580363','lexi-content-ref-15266351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12725868','lexi-content-ref-10580363','lexi-content-ref-15266351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset of symptoms usually occurs within the first day following abrupt withdrawal of lorazepam and any other short- or intermediate-acting benzodiazepines. Long-acting benzodiazepines (eg, diazepam) are associated with an initial onset of withdrawal symptoms 5 days following abrupt discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3092053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3092053'])">Ref</a></span>). In general, persistent post-withdrawal disorder associated with psychotropic medications (eg, benzodiazepines) have an onset ranging from 24 hours to 6 weeks following a decrease, discontinuation, or switch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Benzodiazepines, in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Abrupt discontinuation (rather than gradual dosage reduction) of a benzodiazepine used long-term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3092053','lexi-content-ref-15078112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3092053','lexi-content-ref-15078112'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9559604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9559604'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Chronic dosing (ie, intermittent dosing may reduce the risk of withdrawal symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31271339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31271339'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">• Long treatment durations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1980689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1980689'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Withdrawal-associated seizure: Predisposed patients (eg, brain damage, alcohol abuse, history of seizure, or those receiving agents that lower the seizure threshold) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific benzodiazepine: High-potency benzodiazepines with short and intermediate half-lives, such as lorazepam, are more frequently associated with withdrawal symptoms; benzodiazepines with a short and intermediate half-life have a higher risk for rebound, withdrawal reactions, and dependence compared to long-acting agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F189887"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (IM: 1% to 17%; IV: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness, sedated state</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Coma (≤1%), confusion (≤1%), delirium (≤1%), depression (≤1%), dizziness (7%), excessive crying (≤1%), hallucinations (1%), headache (≤1%), restlessness (≤1%), stupor (≤1%), unsteadiness (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea (1%), hypoventilation (≤1%), respiratory failure (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, sialorrhea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, abnormality in thinking, agitation, ataxia, brain edema, chills, myoclonus, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hyperventilation</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido, hyponatremia, increased lactate dehydrogenase, SIADH</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Changes in appetite, constipation</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence, orgasm disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, leukopenia, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin, increased serum transaminases, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Disinhibition, disorientation, drug dependence, dysarthria, dysautonomia, euphoria, extrapyramidal reaction, fatigue, hypothermia, memory impairment, sleep apnea (exacerbation), slurred speech, suicidal ideation, suicidal tendencies, vertigo, withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Exacerbation of chronic obstructive pulmonary disease, respiratory depression</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Paradoxical reaction (Mancuso 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac arrhythmia, cardiac failure, heart block, pericardial effusion, prolonged QT interval on ECG (Ziegenbein 2004), tachycardia, ventricular arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Pheochromocytoma (aggravation)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disorder of hemostatic components of blood, pulmonary hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Fixed drug eruption (Agulló-García 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (Bond 1988, Pietras 2005), anterograde amnesia (Pandit 1976), nervousness, neuroleptic malignant syndrome, paralysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia (Lucca 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumothorax, pulmonary edema, pulmonary hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Propylene glycol toxicity (IV) (Neale 2005)</p></div>
<div class="block coi drugH1Div" id="F189904"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to lorazepam, any component of the formulation, or other benzodiazepines (cross-sensitivity with other benzodiazepines may exist); acute narrow-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Additional contraindications: Hypersensitivity to polyethylene glycol, propylene glycol, or benzyl alcohol; sleep apnea; intra-arterial injection; use in premature infants; severe respiratory insufficiency (except during mechanical ventilation).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Myasthenia gravis.</p></div>
<div class="block war drugH1Div" id="F189884"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related activities: Hazardous sleep-related activities, such as sleep-driving, cooking and eating food, and making phone calls while asleep, have been noted with benzodiazepines (Dolder 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Avoid use in patients with depression because of concerns about worsening mood symptoms, particularly if suicidal risk may be present, except for acute or emergency situations (eg, acute agitation, status epilepticus) (Craske 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, insufficiency, and/or encephalopathy. Dose adjustment (lower doses) may be needed. May worsen hepatic encephalopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Reduce dose or avoid use in patients with respiratory disease, including chronic obstructive pulmonary disease or sleep apnea. Benzodiazepines may cause significant respiratory depression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Concomitant use with opioids: In patients already receiving an opioid analgesic, prescribe a lower initial dose of lorazepam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking lorazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">• Flumazenil: Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; initial doses should be at the lower end of dosing range.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult patients: Older adult patients may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in older adult dementia patients (Jennum 2015; Saarelainen 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polyethylene glycol: Parenteral formulation may contain polyethylene glycol. May be associated with toxicity in high-dose and/or longer-term therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Some formulations may contain tartrazine (FD&amp;C Yellow No. 5), which may cause allergic-type reactions (including bronchial asthma) in susceptible individuals, particularly those who also have aspirin sensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse, misuse, and substance use disorder: Counsel patients at increased risk on proper use and monitoring for signs and symptoms of abuse, misuse, and substance use disorder. Institute early treatment or refer patients in whom substance use disorder is suspected. Limit dosages and durations to the minimum required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Status epilepticus should not be treated with injectable benzodiazepines alone; requires close observation and management and possibly ventilatory support. When used as a component of preanesthesia, monitor for heavy sedation and airway obstruction; equipment necessary to maintain airway and ventilatory support should be available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Lorazepam is a short half-life benzodiazepine. Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the sedative, hypnotic, and antiseizure effects. It does not develop to the anxiolytic effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878527"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use with caution in neonates, especially in preterm infants; several cases of neurotoxicity and myoclonus (rhythmic myoclonic jerking) have been reported.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol.</p></div>
<div class="block foc drugH1Div" id="F189896"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule ER 24 Hour Sprinkle, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loreev XR: 1 mg [contains corn starch, fd&amp;c yellow #5 (tartrazine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loreev XR: 1.5 mg [contains corn starch, fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loreev XR: 2 mg [contains corn starch, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loreev XR: 3 mg [contains corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LORazepam Intensol: 2 mg/mL (30 mL) [alcohol free, dye free, sugar free; contains polyethylene glycol (macrogol), propylene glycol; unflavored flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ativan: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL) [contains benzyl alcohol, polyethylene glycol (macrogol), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ativan: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ativan: 1 mg, 2 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg</p></div>
<div class="block geq drugH1Div" id="F189880"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F189907"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Sprinkle</b> (Loreev XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $17.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $17.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $17.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $17.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (LORazepam Intensol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $1.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (LORazepam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $1.33 - $10.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ativan Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/mL (per mL): $3.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (LORazepam Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $1.27 - $4.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/mL (per mL): $2.16 - $3.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ativan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $41.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $54.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $87.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (LORazepam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $0.07 - $0.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.07 - $0.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.10 - $1.28</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867398"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL ([DSC]); 4 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ativan: 0.5 mg, 1 mg, 2 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ativan: 0.5 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ativan: 1 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ativan: 2 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg</p></div>
<div class="block exp drugH1Div" id="F11446285"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Commercial oral solution is available (2 mg/mL)</p>
<p style="text-indent:0em;margin-top:2em;">Two different 1 mg/mL oral suspensions may be made from different generic lorazepam tablets (Mylan Pharmaceuticals or Watson Laboratories), sterile water, Ora-Sweet, and Ora-Plus.</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">Mylan tablets: Place one-hundred-eighty 2 mg tablets in a 12-ounce amber glass bottle; add 144 mL of sterile water to disperse the tablets; shake until slurry is formed. Add 108 mL Ora-Plus in incremental proportions; then add a quantity of Ora-Sweet sufficient to make 360 mL. Label "shake well" and "refrigerate". Stable for 91 days when stored in amber glass prescription bottles at room temperature or refrigerated (preferred).</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">Watson tablets: Place one-hundred-eighty 2 mg tablets in a 12-ounce amber glass bottle; add 48 mL sterile water to disperse the tablets; shake until slurry is formed. Add 156 mL of Ora-Plus in incremental proportions; then add a quantity of Ora-Sweet sufficient to make 360 mL. Label "shake well" and "refrigerate". Store in amber glass prescription bottles. Stable for 63 days at room temperature or 91 days refrigerated.</p>
<div class="reference">Lee WM, Lugo RA, Rusho WJ, Mackay M, Sweeley J. Chemical stability of extemporaneously prepared Lorazepam suspension at two temperatures. <i>J Pediatr Pharmacol Ther.</i> 2004;9(4):254-258.</div>
</div>
<div class="block csi drugH1Div" id="F189975"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block admp drugH1Div" id="F52613183"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with food to decrease GI distress; dilute oral solution in water, juice, soda, or semisolid food (eg, applesauce, pudding).</p>
<p style="text-indent:-2em;margin-left:2em;">Intranasal: Administer undiluted (injectable formulation) into one nostril using a needleless syringe or nasal atomizer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16698412','lexi-content-ref-21275979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16698412','lexi-content-ref-21275979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Dilute prior to administration. Do not exceed 2 mg/minute or 0.05 mg/kg over 2 to 5 minutes; administer IV using repeated aspiration with slow IV injection, to make sure the injection is not intra-arterial and that perivascular extravasation has not occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted by deep injection into muscle mass</p></div>
<div class="block adm drugH1Div" id="F189901"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Should be administered (undiluted) deep into the muscle mass.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV injection:</b> Dilute prior to use (according to the manufacturer). Do not exceed 2 mg/minute or 0.05 mg/kg over 2 to 5 minutes. Monitor IV site during administration. Avoid intra-arterial administration. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">ER capsule: Administer with or without food. Do not crush or chew. Swallow whole or open and sprinkle the entire contents of capsule over a tablespoon of applesauce, then drink water after consuming the applesauce (without chewing). Consume entire contents of capsule within 2 hours of opening capsule.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral concentrate: Use only the provided calibrated dropper to withdraw the prescribed dose. Mix the dose with liquid (eg, water, juice, soda, soda-like beverage) or semisolid food (eg, applesauce, pudding), and stir for a few seconds to blend completely. The prepared mixture should be administered immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SubQ (off-label route):</b> Some experts administer the injectable solution subcutaneously when other routes are unavailable (eg, comfort care settings) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-vonGunten.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-vonGunten.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal (off-label route):</b> Injectable solution may be administered rectally when other routes are unavailable (eg, comfort care settings) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3427562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3427562'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sublingual:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral concentrate (off-label route): May be administered sublingually when other routes are unavailable (eg, comfort care settings (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24681184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24681184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral tablet (off-label route): May be administered sublingually when other routes are unavailable (eg, comfort care settings (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6121043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6121043'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual tablet [Canadian product]: Place under tongue; patient should not swallow for at least 2 minutes.</p></div>
<div class="block sts drugH1Div" id="F189918"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Intact vials should be refrigerated (room temperature storage information may be available; contact product manufacturer to obtain current recommendations). Protect from light. Storage of solution diluted for infusion information is not provided in the manufacturer's labeling; refer to individual institutions policies and procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral concentrate: Store at 2°C to 8°C (36°F to 46°F); protect from light. Dispense only in original bottle and only with manufacturer-supplied calibrated dropper; discard open bottle after 90 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral ER capsule: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral IR tablet: Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual tablet [Canadian product]: Store at 15°C to 25°C (59°F to 77°F). Protect from light.</p></div>
<div class="block meg drugH1Div" id="F49468920"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Ativan: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F017794s049lbl.pdf%23page%3D14&amp;token=PCHEU0as%2FLkGByUitDbhqC64BCBUn5KfrAtP9oGvRjaEOCdzcXEvRjkXuBiMbXbGEhuhoK49gT5%2BpelLouNRZIH4rOtQ6fki3uc6AAY%2BEtTR98YRLb9zQdojWllKjIri&amp;TOPIC_ID=12565" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017794s049lbl.pdf#page=14</a></p>
<p style="text-indent:-2em;margin-left:4em;">Loreev XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F214826s003lbl.pdf%23page%3D16&amp;token=hqDk1Wkem6kjwOotIlx%2BcZRS%2FtyVGnk6fI4zAvPe8Y%2FP39DnJxKbZS3zk50d5hyiZl0%2BfRBAxMp7GtIfs04Biw1mWF2OYvhWvySX4iYZBH%2BJZ1MD7t0mmmQZMTXBykY9&amp;TOPIC_ID=12565" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214826s003lbl.pdf#page=16</a></p></div>
<div class="block usep drugH1Div" id="F53567578"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Management of anxiety disorders, short-term relief of symptoms of anxiety, anxiety associated with depressive symptoms (All indications: FDA approved in ages ≥12 years and adults); has also been used for preprocedure sedation</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Treatment of status epilepticus (FDA approved in adults); preoperative sedation, anxiolytic and amnestic (FDA approved in adults); has also been used for breakthrough nausea and vomiting associated with chemotherapy </p></div>
<div class="block mst drugH1Div" id="F189983"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">LORazepam may be confused with ALPRAZolam, clonazePAM, diazePAM, KlonoPIN, Lovaza, temazepam, zolpidem.</p>
<p style="text-indent:0em;margin-left:2em;">Ativan may be confused with Ambien, Atarax, Atgam, Avitene.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Lorazepam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older because of risk of abuse, misuse, physical dependence, and addiction. In addition, older adults have increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use. However, benzodiazepines may be appropriate in the elderly when used for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine or ethanol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Injection dosage form contains propylene glycol. Monitor for toxicity when administering continuous or high-dose lorazepam infusions.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299616"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F189889"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of LORazepam. Alcohol (Ethyl) may increase the serum concentration of LORazepam. Specifically, this increase in concentration would only occur with use of lorazepam extended release capsules and alcohol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ilaprazole: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: May enhance the adverse/toxic effect of LORazepam. Specifically, prolonged stupor, respiratory depression, and/or hypotension.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Products Containing Propylene Glycol. A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Benzodiazepines may enhance the adverse/toxic effect of OLANZapine.  Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: Benzodiazepines may enhance the CNS depressant effect of Oxybate Salt Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of LORazepam. Management: Reduce lorazepam dose 50% during coadministration with probenecid. Monitor for increased and prolonged lorazepam effects, particularly CNS depressant effects. Patients using lorazepam ER capsules should be switched to lorazepam tablets.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyrimethamine: LORazepam may enhance the hepatotoxic effect of Pyrimethamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Propylene Glycol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">UGT2B15 Inhibitors: May increase the serum concentration of LORazepam. Management: Avoid coadministration of UGT2B15 inhibitors and extended release lorazepam capsules. If coadministration is required, discontinue lorazepam extended release capsules and use lorazepam tablets instead. Monitor for increased lorazepam toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of LORazepam. Management: Reduce lorazepam dose 50% during coadministration with valproate products. Monitor for increased lorazepam effects, particularly CNS depression. Patients taking lorazepam extended-release capsules should be switched to lorazepam tablets.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58004535"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use. Pregnancy testing is recommended before treating acute alcohol withdrawal symptoms (ASAM 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Therapy for anxiety should be individualized (BAP [McAllister-Williams 2017]); avoid the use of benzodiazepines for the treatment of anxiety disorders in patients planning to become pregnant (Larsen 2015).</p></div>
<div class="block pri drugH1Div" id="F189908"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Lorazepam and its metabolite cross the human placenta (Kanto 1982; Papini 2006).</p>
<p style="text-indent:0em;margin-top:2em;">In utero exposure to benzodiazepines has the potential to cause harm to the fetus. Teratogenic effects have been observed in some studies; however, a clear association has not been reported and additional data are needed (Bellantuono 2013; Freeman 2018; Grigoriadis 2019; Noh 2022; Szpunar 2022; Tinker 2019; Wikner 2007). Exposure to a benzodiazepine late in pregnancy may cause neonatal sedation (hypotonia, lethargy, respiratory depression) and/or symptoms of neonatal withdrawal (feeding difficulties, hyperreflexia, inconsolable crying, irritability, restlessness, tremors). Data related to long-term effects on neurodevelopment are inconclusive (Chen 2022; Radojčić 2017; Sundbakk 2022; Wang 2022). Newborns exposed to lorazepam in utero should be monitored for feeding problems, respiratory depression, sedation, and withdrawal.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of lorazepam may be altered, resulting in an increased apparent V<sub>d</sub>, increased apparent oral clearance, and decreased elimination half-life (Papini 2006). Elimination of lorazepam in the newborn infant is slow; following in utero exposure, term infants may excrete lorazepam for up to 8 days (Whitelaw 1981).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for alcohol withdrawal may be considered for pregnant patients with at least moderate symptoms (CIWA-Ar scores ≥10) (ASAM 2020). The short-term use of a long-acting benzodiazepine may be used in pregnant patients requiring treatment of acute alcohol withdrawal symptoms (WHO 2014); however, the use of shorter-acting benzodiazepines is preferred in patients at risk for preterm delivery or when treatment is needed during the third trimester (ASAM 2020). Although recommendations vary by guideline, the use of a benzodiazepine other than lorazepam may be preferred during pregnancy (BAP [McAllister-Williams 2017]; SOGC [Graves 2020]; WFSBP/IAWMH [Thibaut 2019]). Monitor newborns for fetal alcohol spectrum disorders in addition to benzodiazepine intoxication (ASAM 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Therapy for anxiety during pregnancy should be individualized. Untreated or inadequately treated psychiatric illness may lead to poor adherence to prenatal care and adverse pregnancy outcomes (ACOG 2008). Benzodiazepines are not preferred when pharmacologic treatment for anxiety disorders is needed during pregnancy, (BAP [McAllister-Williams 2017]; Larsen 2015) and when a benzodiazepine is needed, the use of lorazepam is not preferred. If possible, avoid scheduled doses of benzodiazepines in the month prior to delivery to reduce the risk of withdrawal symptoms in the newborn (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to lorazepam is ongoing. Health care providers are encouraged to enroll patients exposed to lorazepam during pregnancy in the National Pregnancy Registry for Psychiatric Medications (866-961-2388).</p></div>
<div class="block mopp drugH1Div" id="F53567558"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory rate, blood pressure, heart rate.</p>
<p style="text-indent:-2em;margin-left:2em;">Long-term therapy: CBC with differential, liver function tests.</p>
<p style="text-indent:-2em;margin-left:2em;">High dose or continuous IV use: Clinical signs of propylene glycol toxicity, including serum creatinine, BUN, serum lactate, osmol gap.</p></div>
<div class="block pha drugH1Div" id="F189883"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Short-to-intermediate-acting benzodiazepine (based on half-life) (Griffin 2013). Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors.</p></div>
<div class="block phk drugH1Div" id="F189903"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Antiseizure medication: IV: Within 10 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Hypnosis: IM: 20 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Sedation:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 15 to 20 minutes (dose dependent) (Barr 2013; Horn 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 20 to 30 minutes (Horn 2004).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Classified as a short-to-intermediate-acting benzodiazepine; classification based on benzodiazepines with half-life of &lt;40 hours (Griffin 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">Indication specific duration:</p>
<p style="text-indent:-2em;margin-left:6em;">Anesthesia premedication: Adults: IM, IV: ~6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Delayed relative to IV (Leppik 2015; Wermeling 2001); Oral: Readily absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (GA ≥37 weeks): IV: V<sub>d</sub>: 0.76 ± 0.37 L/kg (range: 0.14 to 1.3 L/kg) (McDermott 1992).</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients (Chamberlain 2012): IV: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">5 months to &lt;3 years: 1.62 L/kg (range: 0.67 to 3.4 L/kg).</p>
<p style="text-indent:-2em;margin-left:6em;">3 to &lt;13 years: 1.5 L/kg (range: 0.49 to 3 L/kg).</p>
<p style="text-indent:-2em;margin-left:6em;">13 to &lt;18 years: 1.27 L/kg (range: 1 to 1.54 L/kg).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: V<sub>d</sub>: 1.3 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Extended release: V<sub>d</sub>: 117 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 85% to 91%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; rapidly conjugated to lorazepam glucuronide (inactive).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Full-term neonates: IV: 40.2 ± 16.5 hours; range: 18 to 73 hours (McDermott 1992).</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients (Chamberlain 2012): IV:</p>
<p style="text-indent:-2em;margin-left:6em;">5 months to &lt;3 years: 15.8 hours (range: 5.9 to 28.4 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">3 to &lt;13 years: 16.9 hours (range: 7.5 to 40.6 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">13 to &lt;18 years: 17.8 hours (range: 8.2 to 42 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oral: Extended release: ~20.2 ± 7.2 hours; Immediate release: ~12 hours; IV: ~14 hours; IM: ~13 to 18 hours (Greenblatt 1983); End-stage renal disease (ESRD): ~18 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: ≤3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: 14 hours (range: 7 to 24 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Sublingual tablet [Canadian product]: 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~88%; predominantly as inactive metabolites); feces (~7%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F189910"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo lorazepam | Ativan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aplacasse | Calmatron | Emotival | Kalmalin | Lorazepam fabra | Lorazepam northia | Lorazepam richet | Lorazepam vannier | Lorazepan | Lorazepan lacefa | Lorezan | Microzepam | Nervistop | Nervistop l lacefa | Plardox | Sedatival | Sidenar | Trapax | Trapecis | Tratenamin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Merlit | Temesta</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo lorazepam | Ativan | Bioplus sedacalm | Lorazepam mylan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Lozicum | Trapex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Calmamed | Docloraze | Lauracalm | Lorazemed | Lorazepam efeka | Lorazepam Eurogenerics | Lorazepam mylan | Lorazepam ratiopharm | Lorazepam teva generics belgium | Lorazetop | Loridem | Serenase | Temesta | Vigiten</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Temesta</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lorapam</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lorapan | Lorax | Lorazefast | Max-pax | Mesmerin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Lorasifar | Sedazin | Temesta</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Abinol | Amparax</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jia pu le | Le la an | Lora</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Lorazepam MK | Lorazepan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo lorazepam | Tavor | Temesta</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Duralozam | Laubeel | Lorazepam aristo | Lorazepam CT | Lorazepam Dura | Punktyl | Somagerol | Tavor | Tavor expidet | Tolid</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Lorep | Placinoral | Sedarkey | Sonamin | Tensopan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ativan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Laubeel | Lorans | Temesta</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Apo lorazepam | Ativan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Donix | Idalprem | Lorazepam aristo | Lorazepam Cinfa | Lorazepam desgen | Lorazepam Kern pharma | Lorazepam normon | Lorazepam pensa | Lorazepam vir | Orfidal | Sedicepan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lorazepam orifarm | Lorazepam orion | Temesta | Vanapam</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Equitam | Lorazepam biogaran | Lorazepam merck | Temesta</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Abbloraz | Almazine | Ativan | Lorazepam aps | Lorazepam arrow | Lorazepam astec | Lorazepam berk | Lorazepam cox | Lorazepam dc | Lorazepam kent | Lorazepam sandoz | Lorazepam steinhard</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aripax | Dorm | Modium | Nifalin | Novhepar | Proneurit | Tavor | Titus | Trankilium</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Lora | Lorans | Lorivan | Lotevem | Lozicum | Pms lorazepam | Silence</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lorsilan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Loranxil | Lorazepam Aramis | Rilex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Merlopam | Renaquil</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Azepam</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lorivan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Almazine | Anxilor | Anxipose | Aticool | Atipam | Ativan | Benj | Calmese | Emelor | Jerocen | L pam | L zepam | Larox | Larpose | Lopez | Loracalm | Loranix | Loranza | Lorat | Lorawel | Lorax | Loraz | Lorazen | Lorazin | Lorcin | Lored | Lorel | Lorepa | Loricon | Loripam | Lorivan | Lormac | Lorvan | Loxum | Lozep 2 | Meripose | Neulora | Norpose | Orazep | Pezlor | Psypose | Trapex | Zepnap</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Control | Lorans | Lorazepam abc | Lorazepam actavis | Lorazepam almus | Lorazepam alter | Lorazepam aristo | Lorazepam doc generici | Lorazepam eg | Lorazepam mebel | Lorazepam ranbaxy | Lorazepam ratiopharm | Lorazepam reddy | Lorxagen | Tavor | Zeloram</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Lorans</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Azrogen | Lora pita | Lorazepam towa | Rocosgen | Symplex | U pan | Wypax yamanouchi</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Loravan | Milzepam | Slivan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo lorazepam | Ativan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Lorapam</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lorafen | Lorans | Lorazepam polta | Lorazepam tzf</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Docloraze | Lauracalm | Lorazepam Eurogenerics | Lorazepam mylan | Loridem | Serenase | Temesta | Vigiten</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lorafen</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Lorans | Temesta</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Apolazam | Ativan | Lozam | Plimbox | Sinestron</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo lorazepam | Ativan | Lorans | Tranpam</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lorazepam A | Lorazepam Alpharma | Lorazepam flx | Lorazepam prolepha | Temesta</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lorazepam aristo | Lorazepam nuraxpharm | Lorazepam orifarm | Temesta</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Lorapam | Lorzem</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ativan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ativan</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Arivan | Arsopal | Ativan | Avor | Emotivan | Gtvan | L pam | Lipaz | Lo aram | Loram | Medi-s | Orgalopam | Revel | Tenzil | Tranquil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lorabex | Lorafen | Lorazepam orion | Temesta</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Loreev xr</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ansilor | Lorazepam aristo | Lorazepam Pharmakern | Lorenin | Lorsedal</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Lorans</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Anxiar | Lorivan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Lorafen | Merlit</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ativan</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lorazepam orifarm | Lorazepam orion | Temesta</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo lorazepam | Ativan | Lorans</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Loram | Lorsilan | Temesta</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Tavor expidet</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anta | Anxira | Ativan | Hawkcopax | Kemora | Lonza | Lora | Lora-p | Loramed | Lorans | Lorapam | Lorapine | Lorazene | Lorazep | Lorazin | Lozepine | Ora | Razepam | Tranavan | Vanmed</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Loram | Lorans | Temesta</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ativan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anxicam | Anxiedin | Anzepam | Aramin | Atilen | Atipam | Ativan | Atizepam | Control | Fuletin | Kolinin | Larpam | Lopam | Lorapam | Lorazepan | Lorazin | Lorpin | Lovamin | Lowen | Neuropam | Padelin | Quait | Silence | Spolin | Stapam | Wintin | Wypax</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Atemperator | Ativan | Farmazepan | Lorazepan | Lorazepan Chobet | Solepar | Tranplus</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ativan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ativan | Rolab-lorazepam | Tranqipam</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Apo lorazepam</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6133901">
<a name="6133901"></a>Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. <i>J Lab Clin Med.</i> 1983;101(6):873-880.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6133901/pubmed" id="6133901" target="_blank">6133901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2860136">
<a name="2860136"></a>Adler L, Angrist B, Peselow E, Corwin J, Rotrosen J. Efficacy of propranolol in neuroleptic-induced akathesia. <i>J Clin Psychopharmacol</i>. 1985;5(3):164-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/2860136/pubmed" id="2860136" target="_blank">2860136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29939135">
<a name="29939135"></a>Agulló-García A, Garcés Sotillos M, Colás Sanz C. Fixed drug eruption due to lorazepam. <i>J Investig Allergol Clin Immunol</i>. 2018;28(3):185-186. doi:10.18176/jiaci.0225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/29939135/pubmed" id="29939135" target="_blank">29939135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16698412">
<a name="16698412"></a>Ahmad S, Ellis JC, Kamwendo H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. <i>Lancet</i>. 2006;367(9522):1591-1597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/16698412/pubmed" id="16698412" target="_blank">16698412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12725868">
<a name="12725868"></a>Allison C, Pratt JA. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. <i>Pharmacol Ther</i>. 2003;98(2):171-195. doi:10.1016/s0163-7258(03)00029-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/12725868/pubmed" id="12725868" target="_blank">12725868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28800805">
<a name="28800805"></a>Akerele E, Olupona T. Drugs of abuse. <i>Psychiatr Clin North Am</i>. 2017;40(3):501-517. doi:10.1016/j.psc.2017.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/28800805/pubmed" id="28800805" target="_blank">28800805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol</i>. 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511109">
<a name="32511109"></a>American Society of Addiction Medicine (ASAM). The ASAM clinical practice guideline on alcohol withdrawal management. <i>J Addict Med</i>. 2020:14(3S)(suppl 1):1-72. doi:10.1097/ADM.0000000000000668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/32511109/pubmed" id="32511109" target="_blank">32511109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24594499">
<a name="24594499"></a>Amini A, Heidari K, Asadollahi S, et al. Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo in the emergency department: A double blind, randomized clinical trial of efficacy and safety. <i>J Vestib Res</i>. 2014;24(1):39-47. doi:10.3233/VES-130506<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/24594499/pubmed" id="24594499" target="_blank">24594499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30234674">
<a name="30234674"></a>Amirnovin R, Sanchez-Pinto LN, Okuhara C, et al. Implementation of a risk-stratified opioid and benzodiazepine weaning protocol in a pediatric cardiac ICU. <i>Pediatr Crit Care Med</i>. 2018;19(11):1024-1032. doi:10.1097/PCC.0000000000001719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/30234674/pubmed" id="30234674" target="_blank">30234674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17056842">
<a name="17056842"></a>Anand KJ, Hall RW. Pharmacological therapy for analgesia and sedation in the newborn. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2006;91(6):F448-F453. doi:10.1136/adc.2005.082263<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/17056842/pubmed" id="17056842" target="_blank">17056842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ApoLorazepam.2013.04">
<a name="ApoLorazepam.2013.04"></a>Apo-Lorazepam [product monograph]. Toronto, Ontario, Canada: Apotex Inc; August 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arnold.2019">
<a name="Arnold.2019"></a>Arnold TC, Ryan ML. Acute amphetamine and synthetic cathinone ("bath salt") intoxication. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 30, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al, eds. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. American College of Physicians; 2007:126, 182.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286548">
<a name="15286548"></a>Arroliga AC, Shehab N, McCarthy K, Gonzales JP. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. <i>Crit Care Med</i>. 2004;32(8):1709-1714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15286548/pubmed" id="15286548" target="_blank">15286548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21275979">
<a name="21275979"></a>Arya R, Gulati S, Kabra M, Sahu JK, Kalra V. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. <i>Epilepsia</i>. 2011;52(4):788-793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/21275979/pubmed" id="21275979" target="_blank">21275979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ativan.2019.01">
<a name="Ativan.2019.01"></a>Ativan (lorazepam) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AtivanInj.2021.02">
<a name="AtivanInj.2021.02"></a>Ativan (lorazepam) injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AtivanTabs.2021.02">
<a name="AtivanTabs.2021.02"></a>Ativan (lorazepam) tablet [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19900604">
<a name="19900604"></a>Authier N, Balayssac D, Sautereau M, et al. Benzodiazepine dependence: focus on withdrawal syndrome. <i>Ann Pharm Fr</i>. 2009;67(6):408-413. doi:10.1016/j.pharma.2009.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/19900604/pubmed" id="19900604" target="_blank">19900604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15829394">
<a name="15829394"></a>Bahn EL, Holt KR. Procedural sedation and analgesia: a review and new concepts. <i>Emerg Med Clin North Am</i>. 2005;23(2):503-517. doi:10.1016/j.emc.2004.12.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15829394/pubmed" id="15829394" target="_blank">15829394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16422667">
<a name="16422667"></a>Barnes BJ, Gerst C, Smith JR, Terrell AR, Mullins ME. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. <i>Pharmacotherapy.</i> 2006;26(1):23-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/16422667/pubmed" id="16422667" target="_blank">16422667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23269131">
<a name="23269131"></a>Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. <i>Crit Care Med</i>. 2013;41(1):263-306. doi:10.1097/CCM.0b013e3182783b72<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/23269131/pubmed" id="23269131" target="_blank">23269131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2884681">
<a name="2884681"></a>Bartels M, Heide K, Mann K, Schied HW. Treatment of akathisia with lorazepam. An open clinical trial. <i>Pharmacopsychiatry</i>. 1987;20(2):51-53. doi:10.1055/s-2007-1017074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/2884681/pubmed" id="2884681" target="_blank">2884681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32267799">
<a name="32267799"></a>Basura GJ, Adams ME, Monfared A, et al. Clinical practice guideline: Ménière's disease. <i>Otolaryngol Head Neck Surg</i>. 2020;162(2)(suppl):S1-S55. doi:10.1177/0194599820909438<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/32267799/pubmed" id="32267799" target="_blank">32267799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22428972">
<a name="22428972"></a>Becker DE. Pharmacodynamic considerations for moderate and deep sedation. <i>Anesth Prog</i>. 2012;59(1):28-42. doi:10.2344/0003-3006-59.1.28<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22428972/pubmed" id="22428972" target="_blank">22428972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23044244">
<a name="23044244"></a>Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. <i>Gen Hosp Psychiatry</i>. 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/23044244/pubmed" id="23044244" target="_blank">23044244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28248609">
<a name="28248609"></a>Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). <i>Otolaryngol Head Neck Surg</i>. 2017;156(3)(suppl):S1-S47. doi:10.1177/0194599816689667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/28248609/pubmed" id="28248609" target="_blank">28248609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11307041">
<a name="11307041"></a>Blin O, Simon N, Jouve E, et al. Pharmacokinetic and pharmacodynamic analysis of sedative and amnesic effects of lorazepam in healthy volunteers. <i>Clin Neuropharmacol</i>. 2001;24(2):71-81. doi:10.1097/00002826-200103000-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/11307041/pubmed" id="11307041" target="_blank">11307041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3137624">
<a name="3137624"></a>Bond A, Lader M. Differential effects of oxazepam and lorazepam on aggressive responding. <i>Psychopharmacology (Berl)</i>. 1988;95(3):369-373. doi:10.1007/BF00181949<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/3137624/pubmed" id="3137624" target="_blank">3137624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Boyer.2019a">
<a name="Boyer.2019a"></a>Boyer EW. Serotonin syndrome (serotonin toxicity). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Boyer.2019b">
<a name="Boyer.2019b"></a>Boyer EW, Seifert SA, Hernon C. Methamphetamine: Acute intoxication. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 30, 2019b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27124045">
<a name="27124045"></a>Bulathsinghala M, Keefer K, Van de Louw A. Trimethoprim/Sulfamethoxazole-induced severe lactic acidosis: A case report and review of the literature. <i>Medicine (Baltimore)</i>. 2016;95(17):e3478. doi:10.1097/MD.0000000000003478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/27124045/pubmed" id="27124045" target="_blank">27124045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6132612">
<a name="6132612"></a>Burtles R, Astley B. Lorazepam in children. A double-blind trial comparing lorazepam, diazepam, trimeprazine and placebo. <i>Br J Anaesth</i>. 1983;55(4):275-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6132612/pubmed" id="6132612" target="_blank">6132612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8686484">
<a name="8686484"></a>Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. <i>Acta Psychiatr Scand. </i>1996;93(2):137-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/8686484/pubmed" id="8686484" target="_blank">8686484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3092053">
<a name="3092053"></a>Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. <i>N Engl J Med</i>. 1986;315(14):854-859. doi:10.1056/NEJM198610023151403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/3092053/pubmed" id="3092053" target="_blank">3092053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6132630">
<a name="6132630"></a>Caillé G, Spénard J, Lacasse Y, Brennan J. Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. <i>Biopharm Drug Dispos</i>. 1983;4(1):31-42. doi:10.1002/bdd.2510040106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6132630/pubmed" id="6132630" target="_blank">6132630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9559604">
<a name="9559604"></a>Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. <i>Crit Care Med</i>. 1998;26(4):676-84. doi:10.1097/00003246-199804000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/9559604/pubmed" id="9559604" target="_blank">9559604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16540958">
<a name="16540958"></a>Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. <i>Crit Care Med</i>. 2006;34(5):1326-1332. doi: 10.1097/01.CCM.0000215513.63207.7F.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/16540958/pubmed" id="16540958" target="_blank">16540958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8605792">
<a name="8605792"></a>Cernaianu AC, DelRossi AJ, Flum DR, et al. Lorazepam and midazolam in the intensive care unit: a randomized, prospective, multicenter study of hemodynamics, oxygen transport, efficacy, and cost. <i>Crit Care Med</i>. 1996;24(2):222-228. doi:10.1097/00003246-199602000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/8605792/pubmed" id="8605792" target="_blank">8605792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22050870">
<a name="22050870"></a>Chamberlain JM, Capparelli EV, Brown KM, et al. Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. <i>J Pediatr</i>. 2012;160(4):667-672.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22050870/pubmed" id="22050870" target="_blank">22050870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26185424">
<a name="26185424"></a>Chang DH, Hiss S, Herich L, et al. Implantation of venous access devices under local anesthesia: patients' satisfaction with oral lorazepam. <i>Patient Prefer Adherence</i>. 2015;9:943-949. doi:10.2147/PPA.S80330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/26185424/pubmed" id="26185424" target="_blank">26185424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36413366">
<a name="36413366"></a>Chen VC, Wu SI, Lin CF, Lu ML, Chen YL, Stewart R. Association of prenatal exposure to benzodiazepines with development of autism spectrum and attention-deficit/hyperactivity disorders. <i>JAMA Netw Open</i>. 2022;5(11):e2243282. doi:10.1001/jamanetworkopen.2022.43282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/36413366/pubmed" id="36413366" target="_blank">36413366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12483068">
<a name="12483068"></a>Chicella M, Jansen P, Parthiban A, et al. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients. <i>Crit Care Med</i>. 2002;30(12):2752-2756. doi:10.1097/00003246-200212000-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/12483068/pubmed" id="12483068" target="_blank">12483068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15078112">
<a name="15078112"></a>Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. <i>J Clin Psychiatry</i>. 2004;65(suppl 5):7-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15078112/pubmed" id="15078112" target="_blank">15078112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Choy.2019">
<a name="Choy.2019"></a>Choy Y. Acute procedural anxiety and specific phobia of clinical procedures in adults: Treatment overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 30, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Coffey.2019">
<a name="Coffey.2019"></a>Coffey MJ. Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Coffey.2019.1">
<a name="Coffey.2019.1"></a>Coffey MJ. Catatonia: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 15, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32259826">
<a name="32259826"></a>Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. <i>Psychother Psychosom</i>. 2020;89(5):283-306. doi:10.1159/000506868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/32259826/pubmed" id="32259826" target="_blank">32259826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.1">
<a name="Craske.1"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3808299">
<a name="3808299"></a>Crawford TO, Mitchell WG, Snodgrass SR. Lorazepam in Childhood Status Epilepticus and Serial Seizures: Effectiveness and Tachyphylaxis. <i>Neurology. </i>1987;37(2):190-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/3808299/pubmed" id="3808299" target="_blank">3808299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1684055">
<a name="1684055"></a>Curran HV. Benzodiazepines, memory and mood: a review. <i>Psychopharmacology (Berl)</i>. 1991;105(1):1-8. doi:10.1007/BF02316856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/1684055/pubmed" id="1684055" target="_blank">1684055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3114788">
<a name="3114788"></a>Curran HV, Schiwy W, Lader M. Differential amnesic properties of benzodiazepines: a dose-response comparison of two drugs with similar elimination half-lives. <i>Psychopharmacology (Berl)</i>. 1987;92(3):358-364. doi:10.1007/BF00210844<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/3114788/pubmed" id="3114788" target="_blank">3114788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19996245">
<a name="19996245"></a>Daniels J. Catatonia: clinical aspects and neurobiological correlates. <i>J Neuropsychiatry Clin Neurosci</i>. 2009;21(4):371-380. doi:10.1176/appi.neuropsych.21.4.371.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/19996245/pubmed" id="19996245" target="_blank">19996245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18570226">
<a name="18570226"></a>Dawson J, Boyle J, Stanley N, Johnsen S, Hindmarch I, Skene DJ. Benzodiazepine-induced reduction in activity mirrors decrements in cognitive and psychomotor performance. <i>Hum Psychopharmacol</i>. 2008;23(7):605-613. doi:10.1002/hup.961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18570226/pubmed" id="18570226" target="_blank">18570226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15924505">
<a name="15924505"></a>Delcò F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dose adjustment in patients with liver disease. <i>Drug Saf</i>. 2005;28(6):529-545. doi:10.2165/00002018-200528060-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15924505/pubmed" id="15924505" target="_blank">15924505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3752014">
<a name="3752014"></a>Deshmukh A, Wittert W, Schnitzler E, Mangurten HH. Lorazepam in the treatment of refractory neonatal seizures. A pilot study. <i>Am J Dis Child</i>. 1986;140(10):1042-1044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/3752014/pubmed" id="3752014" target="_blank">3752014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28539164">
<a name="28539164"></a>Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, et al. Relationship between the use of benzodiazepines and falls in older adults: A systematic review. <i>Maturitas</i>. 2017;101:17-22. doi:10.1016/j.maturitas.2017.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/28539164/pubmed" id="28539164" target="_blank">28539164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18998740">
<a name="18998740"></a>Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. <i>CNS Drugs</i>. 2008;22(12):1021-1036. doi:10.2165/0023210-200822120-00005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18998740/pubmed" id="18998740" target="_blank">18998740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16720707">
<a name="16720707"></a>Dominguez KD, Crowley MR, Coleman DM, Katz RW, Wilkins DG, Kelly HW. Withdrawal from lorazepam in critically ill children. <i>Ann Pharmacother</i>. 2006;40(6):1035-1039. doi:10.1345/aph.1G701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/16720707/pubmed" id="16720707" target="_blank">16720707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drappatz.2019">
<a name="Drappatz.2019"></a>Drappatz J, Avila EK. Seizures in patients with primary and metastatic brain tumors. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drislane.2019">
<a name="Drislane.2019"></a>Drislane FW. Convulsive status epilepticus in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12956617">
<a name="12956617"></a>Dupuis LL, Nathan PC. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. <i>Paediatr Drugs.</i> 2003;5(9):597-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/12956617/pubmed" id="12956617" target="_blank">12956617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24753095">
<a name="24753095"></a>Dupuis LL, Robinson PD, Boodhan S, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2014;61(8):1506-1512. doi: 10.1002/pbc.25063.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/24753095/pubmed" id="24753095" target="_blank">24753095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21677256">
<a name="21677256"></a>England ML, Ongür D, Konopaske GT, Karmacharya R. Catatonia in psychotic patients: clinical features and treatment response. <i>J Neuropsychiatry Clin Neurosci</i>. 2011;23(2):223-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/21677256/pubmed" id="21677256" target="_blank">21677256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2017">
<a name="FDA.2017"></a>Food and Drug Administration. General Anesthetic and sedation drugs; drug safety communication - FDA approves label changes for use in young children. Food and Drug Administration website. Accessed July 6, 2017. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-use-general-anesthetic-and-sedation-drugs" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-use-general-anesthetic-and-sedation-drugs</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2016">
<a name="FDA.2016"></a>Food and Drug Administration. FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. Food and Drug Administration website. Published December 14, 2016. Updated March 8, 2018. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-results-new-warnings-about-using-general-anesthetics-and" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-results-new-warnings-about-using-general-anesthetics-and</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884605">
<a name="19884605"></a>Fink M, Taylor MA. The catatonia syndrome: forgotten but not gone. <i>Arch Gen Psychiatry</i>. 2009;66(11):1173-7. doi:10.1001/archgenpsychiatry.2009.141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/19884605/pubmed" id="19884605" target="_blank">19884605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30921252">
<a name="30921252"></a>Fishman DS, Andropoulos DB, Lightdale JR. Sedation and the Food and Drug Administration Warning: What a Pediatric Gastroenterologist, Hepatologist, and Pancreatologist Should Know. <i>J Pediatr Gastroenterol Nutr</i>. 2019;69(1):3-5. doi:10.1097/MPG.0000000000002346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/30921252/pubmed" id="30921252" target="_blank">30921252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22093817">
<a name="22093817"></a>Franck LS, Scoppettuolo LA, Wypij D, Curley MAQ. Validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients. <i>Pain</i>. 2012;153(1):142-148. doi:10.1016/j.pain.2011.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22093817/pubmed" id="22093817" target="_blank">22093817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18625822">
<a name="18625822"></a>Frank C. Recognition and treatment of serotonin syndrome. <i>Can Fam Physician</i>. 2008;54(7):988-992.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18625822/pubmed" id="18625822" target="_blank">18625822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4041699">
<a name="4041699"></a>Fraser AA, Ingram IM. Lorazepam dependence and chronic psychosis. <i>Br J Psychiatry</i>. 1985;147:211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/4041699/pubmed" id="4041699" target="_blank">4041699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29958100">
<a name="29958100"></a>Freeman MP, Góez-Mogollón L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders.<i> Gen Hosp Psychiatry</i>. 2018;53:73-79. doi:10.1016/j.genhosppsych.2018.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/29958100/pubmed" id="29958100" target="_blank">29958100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furman.2019">
<a name="Furman.2019"></a>Furman JM, Barton JJS. Treatment of vertigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26322116">
<a name="26322116"></a>Gershkovich P, Wasan KM, Ribeyre C, Ibrahim F, McNeill JH. Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. <i>Drugs Context</i>. 2015;4:212287. doi:10.7573/dic.212287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/26322116/pubmed" id="26322116" target="_blank">26322116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20138190">
<a name="20138190"></a>Giersch A, Boucart M, Elliott M, Vidailhet P. Atypical behavioural effects of lorazepam: clues to the design of novel therapies? <i>Pharmacol Ther</i>. 2010;126(1):94-108. doi:10.1016/j.pharmthera.2010.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/20138190/pubmed" id="20138190" target="_blank">20138190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900382">
<a name="26900382"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/26900382/pubmed" id="26900382" target="_blank">26900382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15198">
<a name="15198"></a>Goldney RD. Paradoxical reaction to a new minor tranquilizer. <i>Med J Aust</i>. 1977;1(5):139-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15198/pubmed" id="15198" target="_blank">15198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33509654">
<a name="33509654"></a>Grabowski J, Goldin A, Arthur LG, et al. The effects of early anesthesia on neurodevelopment: A systematic review. <i>J Pediatr Surg</i>. 2021:S0022-3468(21)00014-2. doi:10.1016/j.jpedsurg.2021.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/33509654/pubmed" id="33509654" target="_blank">33509654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28915132">
<a name="28915132"></a>Graham MR. Clinical update regarding general anesthesia-associated neurotoxicity in infants and children. <i>Curr Opin Anaesthesiol</i>. 2017;30(6):682-687. doi:10.1097/ACO.0000000000000520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/28915132/pubmed" id="28915132" target="_blank">28915132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32900457">
<a name="32900457"></a>Graves L, Carson G, Poole N, et al. Guideline no. 405: screening and counselling for alcohol consumption during pregnancy. <i>J Obstet Gynaecol Can</i>. 2020;42(9):1158-1173.e1. doi:10.1016/j.jogc.2020.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/32900457/pubmed" id="32900457" target="_blank">32900457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3427562">
<a name="3427562"></a>Graves NM, Kriel RL, Jones-Saete C. Bioavailability of rectally administered lorazepam. <i>Clin Neuropharmacol</i>. 1987;10(6):555-559. doi:10.1097/00002826-198712000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/3427562/pubmed" id="3427562" target="_blank">3427562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6121043">
<a name="6121043"></a>Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. <i>J Pharm Sci</i>. 1982;71(2):248-252. doi:10.1002/jps.2600710227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6121043/pubmed" id="6121043" target="_blank">6121043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6135156">
<a name="6135156"></a>Greenblatt DJ, Shader RI, and Abernethy DR. Drug therapy. Current status of benzodiazepines. <i>N Engl J Med</i>. 1983;309(6):354-358.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6135156/pubmed" id="6135156" target="_blank">6135156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23789008">
<a name="23789008"></a>Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. <i>Ochsner J</i>. 2013;13(2):214-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/23789008/pubmed" id="23789008" target="_blank">23789008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31294935">
<a name="31294935"></a>Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. <i>J Clin Psychiatry</i>. 2019;80(4):18r12412. doi:10.4088/JCP.18r12412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/31294935/pubmed" id="31294935" target="_blank">31294935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29774154">
<a name="29774154"></a>Grønbæk L, Watson H, Vilstrup H, Jepsen P. Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites. <i>United European Gastroenterol J</i>. 2018;6(3):407-412. doi:10.1177/2050640617727179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/29774154/pubmed" id="29774154" target="_blank">29774154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21507125">
<a name="21507125"></a>Guerra GG, Robertson CM, Alton GY, et al; Western Canadian Complex Pediatric Therapies Follow-up Group. Neurodevelopmental outcome following exposure to sedative and analgesic drugs for complex cardiac surgery in infancy. <i>Paediatr Anaesth</i>. 2011;21(9):932-941. doi:10.1111/j.1460-9592.2011.03581.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/21507125/pubmed" id="21507125" target="_blank">21507125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12521357">
<a name="12521357"></a>Hain TC, Uddin M. Pharmacological treatment of vertigo. <i>CNS Drugs</i>. 2003;17(2):85-100. doi: 10.2165/00023210-200317020-00002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/12521357/pubmed" id="12521357" target="_blank">12521357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29325983">
<a name="29325983"></a>Hanna J, Swetter S. A case of delirium and rhabdomyolysis in severe Iatrogenic opioid withdrawal. <i>Psychosomatics</i>. 2018;59(4):405-407. doi:10.1016/j.psym.2017.12.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/29325983/pubmed" id="29325983" target="_blank">29325983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472950">
<a name="26472950"></a>Hansen L, Lange R, Gupta S. Development and evaluation of a guideline for monitoring propylene glycol toxicity in pediatric intensive care unit patients receiving continuous infusion lorazepam. <i>J Pediatr Pharmacol Ther</i>. 2015;20(5):367-372. doi:10.5863/1551-6776-20.5.367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/26472950/pubmed" id="26472950" target="_blank">26472950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Harman.2019">
<a name="Harman.2019"></a>Harman SM, Walling AM. Palliative care: The last hours and days of life. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.<i> World J Biol Psychiatry</i>. 2012;13(5):318-378. doi:10.3109/15622975.2012.696143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23216388">
<a name="23216388"></a>Hasan A, Falkai P, Wobrock T, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World J Biol Psychiatry</i>. 2013;14(1):2-44. doi:10.3109/15622975.2012.739708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/23216388/pubmed" id="23216388" target="_blank">23216388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA; American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1934919">
<a name="1934919"></a>Henry DW, Burwinkle JW, Klutman NE. Determination of sedative and amnestic doses of lorazepam in children. <i>Clin Pharm.</i> 1991;10(8):625-629.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/1934919/pubmed" id="1934919" target="_blank">1934919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hoffman.2019">
<a name="Hoffman.2019"></a>Hoffman RS, Weinhouse GL. Management of moderate and severe alcohol withdrawal syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 28, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holt.1">
<a name="Holt.1"></a>Holt S, Tetrault J. Alcohol withdrawal: ambulatory management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 28, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19920159">
<a name="19920159"></a>Horinek EL, Kiser TH, Fish DN, MacLaren R. Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions. <i>Ann Pharmacother</i>. 2009;43(12):1964-1971. doi:10.1345/aph.1M313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/19920159/pubmed" id="19920159" target="_blank">19920159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15121142">
<a name="15121142"></a>Horn E, Nesbit SA. Pharmacology and pharmacokinetics of sedatives and analgesics. <i>Gastrointest Endosc Clin N Am</i>. 2004;14(2):247-268. doi:10.1016/j.giec.2004.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15121142/pubmed" id="15121142" target="_blank">15121142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24681184">
<a name="24681184"></a>Howard P, Twycross R, Shuster J, Mihalyo M, Wilcock A. Benzodiazepines. <i>J Pain Symptom Manage</i>. 2014;47(5):955-964. doi: 10.1016/j.jpainsymman.2014.03.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/24681184/pubmed" id="24681184" target="_blank">24681184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9872743">
<a name="9872743"></a>Ikonomidou C, Bosch F, Miksa M, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. <i>Science</i>. 1999;283(5398):70-4. doi:10.1126/science.283.5398.70<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/9872743/pubmed" id="9872743" target="_blank">9872743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11773648">
<a name="11773648"></a>Iqbal MM, Sobhan T, Ryals T, et al. Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant. <i>Psychiatr Serv.</i> 2002;53(1):39-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/11773648/pubmed" id="11773648" target="_blank">11773648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32426747">
<a name="32426747"></a>Iqbal O'Meara AM, Miller Ferguson N, Zven SE, et al. Potential neurodevelopmental effects of pediatric intensive care sedation and analgesia: Repetitive benzodiazepine and opioid exposure alters expression of glial and synaptic proteins in juvenile rats. <i>Crit Care Explor</i>. 2020;2(4):e0105. doi:10.1097/CCE.0000000000000105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/32426747/pubmed" id="32426747" target="_blank">32426747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Irwin.2019">
<a name="Irwin.2019"></a>Irwin SA, Hirst JM. Overview of anxiety in palliative care. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29392569">
<a name="29392569"></a>Jahn A, Bodreau C, Farthing K, Elbarbry F. Assessing propylene glycol toxicity in alcohol withdrawal patients receiving intravenous benzodiazepines: A one-compartment pharmacokinetic model. <i>Eur J Drug Metab Pharmacokinet</i>. 2018;43(4):423-430. doi: 10.1007/s13318-018-0462-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/29392569/pubmed" id="29392569" target="_blank">29392569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26342397">
<a name="26342397"></a>Jennum P, Baandrup L, Ibsen R, et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. <i>Eur Neuropsychopharmacol.</i> 2015;25(11):1906-1913. doi:10.1016/j.euroneuro.2015.08.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/26342397/pubmed" id="26342397" target="_blank">26342397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11813472">
<a name="11813472"></a>Johnson TJ, Voss G. Continuous infusion of undiluted lorazepam injection. <i>Am J Health Syst Pharm</i>. 2002;59(1):78-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/11813472/pubmed" id="11813472" target="_blank">11813472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12186578">
<a name="12186578"></a>Kalachnik JE, Hanzel TE, Sevenich R, Harder SR. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. <i>Am J Ment Retard</i>. 2002;107(5):376-410. doi:10.1352/0895-8017(2002)107&lt;0376:BBSERA&gt;2.0.CO;2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/12186578/pubmed" id="12186578" target="_blank">12186578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6124415">
<a name="6124415"></a>Kanto JH. Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations. <i>Drugs</i>. 1982;23(5):354-380. doi:10.2165/00003495-198223050-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6124415/pubmed" id="6124415" target="_blank">6124415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22504099">
<a name="22504099"></a>Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. <i>J Pediatr</i>. 2012;161(3):448-451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22504099/pubmed" id="22504099" target="_blank">22504099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khaldarov.2000">
<a name="Khaldarov.2000"></a>Khaldarov N. Benzodiazepines for treatment of neuroleptic malignant syndrome. <i>Hosp Physician</i>. 2000:36(9);51-55.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22298396">
<a name="22298396"></a>Kirkby KC, Montgomery IM, Badcock R, Daniels BA. A comparison of age-related deficits in memory and frontal lobe function following oral lorazepam administration. <i>J Psychopharmacol</i>. 1995;9(4):319-25. doi:10.1177/026988119500900405<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22298396/pubmed" id="22298396" target="_blank">22298396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2011">
<a name="Kliegman.2011"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Saunders Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2020">
<a name="Kliegman.2020"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28871">
<a name="28871"></a>Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR. Effects of aging and liver disease on disposition of lorazepam. <i>Clin Pharmacol Ther.</i> 1978;24(4):411-419. doi:10.1002/cpt1978244411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/28871/pubmed" id="28871" target="_blank">28871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21714826">
<a name="21714826"></a>Lader M. Benzodiazepines revisited--will we ever learn? <i>Addiction</i>. 2011;106(12):2086-2109. doi:10.1111/j.1360-0443.2011.03563.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/21714826/pubmed" id="21714826" target="_blank">21714826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lavonas.1">
<a name="Lavonas.1"></a>Lavonas EJ. First-generation (typical) antipsychotic medication poisoning. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555647">
<a name="17555647"></a>Lemmer P, Schneider S, Mühe A, Wennig R. Quantification of lorazepam and lormetazepam in human breast milk using GC-MS in the negative chemical ionization mode. <i>J Anal Toxicol</i>. 2007;31(4):224-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/17555647/pubmed" id="17555647" target="_blank">17555647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26071998">
<a name="26071998"></a>Leppik IE, Patel SI. Intramuscular and rectal therapies of acute seizures. <i>Epilepsy Behav</i>. 2015;49:307-312. doi:10.1016/j.yebeh.2015.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/26071998/pubmed" id="26071998" target="_blank">26071998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18585543">
<a name="18585543"></a>Levin TT, Cortes-Ladino A, Weiss M, Palomba ML. Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion. <i>Gen Hosp Psychiatry</i>. 2008;30(4):372-377. doi:10.1016/j.genhosppsych.2008.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18585543/pubmed" id="18585543" target="_blank">18585543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25762872">
<a name="25762872"></a>Lim TY, Poole RL, Pageler NM. Propylene glycol toxicity in children. <i>J Pediatr Pharmacol Ther</i>. 2014;19(4):277-282. doi:10.5863/1551-6776-19.4.277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/25762872/pubmed" id="25762872" target="_blank">25762872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1677237">
<a name="1677237"></a>Little JD, Taghavi EH. Disinhibition after lorazepam augmentation of antipsychotic medication. <i>Am J Psychiatry</i>. 1991;148(8):1099-100. doi:10.1176/ajp.148.8.1099a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/1677237/pubmed" id="1677237" target="_blank">1677237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18391612">
<a name="18391612"></a>Lohr L. Chemotherapy-induced nausea and vomiting. <i>Cancer J</i>. 2008;14(2):85-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18391612/pubmed" id="18391612" target="_blank">18391612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24720509">
<a name="24720509"></a>Lonardo NW, Mone MC, Nirula R, et al. Propofol is associated with favorable outcomes compared with benzodiazepines in ventilated intensive care unit patients [published correction appears in <i>Am J Respir Crit Care Med</i>. 2014;189(11):e70]. <i>Am J Respir Crit Care Med</i>. 2014;189(11):1383-1394. doi:10.1164/rccm.201312-2291OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/24720509/pubmed" id="24720509" target="_blank">24720509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lorazepam.2011.06">
<a name="Lorazepam.2011.06"></a>Lorazepam injection [prescribing information]. Eatontown, NJ: West-ward Pharmaceuticals; June 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Lorazepam injection USP solution 2 mg/mL (lorazepam) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LorazepamInj.2019.08">
<a name="LorazepamInj.2019.08"></a>Lorazepam injection USP sterile solution 4 mg/mL (lorazepam) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LorazepamOral.2021.03">
<a name="LorazepamOral.2021.03"></a>Lorazepam oral concentrate [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LorazepamTabs">
<a name="LorazepamTabs"></a>Lorazepam tablets [prescribing information]. Columbus, OH: American Health Packaging.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LoreevXR.1">
<a name="LoreevXR.1"></a>Loreev XR capsules [prescribing information]. Morristown, NJ: Almatica Pharma LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24741200">
<a name="24741200"></a>Lucca JM, Ramesh M, Parthasarathi G, Ram D. Lorazepam-induced diplopia. <i>Indian J Pharmacol</i>. 2014;46(2):228-229. doi:10.4103/0253-7613.129328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/24741200/pubmed" id="24741200" target="_blank">24741200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12047731">
<a name="12047731"></a>Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial.<i> J Gen Intern Med</i>. 2002;17(5):349-355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/12047731/pubmed" id="12047731" target="_blank">12047731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6144317">
<a name="6144317"></a>Male CG, Johnson HD. Oral benzodiazepine premedication in minor gynaecological surgery.<i> Br J Anaesth</i>. 1984;56(5):499-507. doi:10.1093/bja/56.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6144317/pubmed" id="6144317" target="_blank">6144317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15460178">
<a name="15460178"></a>Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. <i>Pharmacotherapy</i>. 2004;24(9):1177-1185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15460178/pubmed" id="15460178" target="_blank">15460178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11020677">
<a name="11020677"></a>Marill KA, Walsh MJ, Nelson BK. Intravenous lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. <i>Ann Emerg Med</i>. 2000;36(4):310-319. doi:10.1067/mem.2000.110580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/11020677/pubmed" id="11020677" target="_blank">11020677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1940133">
<a name="1940133"></a>Maytal J, Novak GP, King KC. Lorazepam in the treatment of refractory neonatal seizures. <i>J Child Neurol</i>. 1991;6(4):319-323.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/1940133/pubmed" id="1940133" target="_blank">1940133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440103">
<a name="28440103"></a>McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017.<i> J Psychopharmacol</i>. 2017;31(5):519-552. doi:10.1177/0269881117699361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/28440103/pubmed" id="28440103" target="_blank">28440103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1538303">
<a name="1538303"></a>McDermott CA, Kowalczyk AL, Schnitzler ER, et al. Pharmacokinetics of Lorazepam in Critically Ill Neonates With Seizures. <i>J Pediatr. </i>1992;120(3):479-483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/1538303/pubmed" id="1538303" target="_blank">1538303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25583219">
<a name="25583219"></a>McKee HR, Abou-Khalil B. Outpatient pharmacotherapy and modes of administration for acute repetitive and prolonged seizures. <i>CNS Drugs</i>. 2015;29(1):55-70. doi:10.1007/s40263-014-0219-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/25583219/pubmed" id="25583219" target="_blank">25583219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23413121">
<a name="23413121"></a>McPherson C. Sedation and analgesia in mechanically ventilated preterm neonates: continue standard of care or experiment? <i>J Pediatr Pharmacol Ther</i>. 2012;17(4):351-364. doi:10.5863/1551-6776-17.4.351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/23413121/pubmed" id="23413121" target="_blank">23413121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1357612">
<a name="1357612"></a>Mejo SL. Anterograde amnesia linked to benzodiazepines. <i>Nurse Pract</i>. 1992;17(10):44, 49-50. doi:10.1097/00006205-199210000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/1357612/pubmed" id="1357612" target="_blank">1357612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moore.2019">
<a name="Moore.2019"></a>Moore GP, Moore MJ. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 6, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33224688">
<a name="33224688"></a>Moore TA. Ambulatory detoxification in alcohol use disorder and opioid use disorder. <i>Ment Health Clin</i>. 2020b;10(6):307-316. doi:10.9740/mhc.2020.11.307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/33224688/pubmed" id="33224688" target="_blank">33224688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6713774">
<a name="6713774"></a>Morrison G, Chiang ST, Koepke HH, Walker BR. Effect of renal impairment and hemodialysis on lorazepam kinetics. <i>Clin Pharmacol Ther</i>. 1984;35(5):646-652. doi:10.1038/clpt.1984.89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6713774/pubmed" id="6713774" target="_blank">6713774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6109421">
<a name="6109421"></a>Mundeleer P. Child premedication per os with lorazepam. <i>Acta Anaesthesiol Belg</i>. 1980;(31)(suppl):187-193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6109421/pubmed" id="6109421" target="_blank">6109421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19485969">
<a name="19485969"></a>Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. <i>Alcohol Clin Exp Res</i>. 2009;33(9):1582-1588. doi:10.1111/j.1530-0277.2009.00986.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/19485969/pubmed" id="19485969" target="_blank">19485969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2012">
<a name="NICE.2012"></a>National Institute for Health and Care Excellence (NICE). Epilepsies: diagnosis and management. https://www.nice.org.uk/guidance/cg137/resources/epilepsies-diagnosis-and-management-35109515407813 Published January 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16159998">
<a name="16159998"></a>Neale BW, Mesler EL, Young M, Rebuck JA, Weise WJ. Propylene glycol-induced lactic acidosis in a patient with normal renal function: a proposed mechanism and monitoring recommendations. <i>Ann Pharmacother</i>. 2005;39(10):1732-1736. doi:10.1345/aph.1G083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/16159998/pubmed" id="16159998" target="_blank">16159998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18543419">
<a name="18543419"></a>Nelsen JL, Haas CE, Habtemariam B, et al. A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. <i>J Intensive Care Med</i>. 2008;23(3):184-194. doi:10.1177/0885066608315808<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18543419/pubmed" id="18543419" target="_blank">18543419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519733">
<a name="10519733"></a>Nelson J, Chouinard G; Canadian Society for Clinical Pharmacology. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. <i>Can J Clin Pharmacol.</i> 1999;6(2):69-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/10519733/pubmed" id="10519733" target="_blank">10519733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.2019">
<a name="Nelson.2019"></a>Nelson L, Odujebe O. Cocaine: Acute intoxication. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24675625">
<a name="24675625"></a>Nelson MA, Bradshaw WT. Use of benzodiazepines as anxiolytics in neonates: are we there yet?. <i>Adv Neonatal Care</i>. 2014;14(2):78-87. doi:10.1097/ANC.0000000000000049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/24675625/pubmed" id="24675625" target="_blank">24675625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33449825">
<a name="33449825"></a>Nishimura A, Furugen A, Umazume T, et al. Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. <i>Breastfeed Med</i>. 2021;16(5):424-431. doi:10.1089/bfm.2020.0259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/33449825/pubmed" id="33449825" target="_blank">33449825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35235572">
<a name="35235572"></a>Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: a population-based cohort study in South Korea. <i>PLoS Med</i>. 2022;19(3):e1003945. doi:10.1371/journal.pmed.1003945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/35235572/pubmed" id="35235572" target="_blank">35235572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1980689">
<a name="1980689"></a>Nutt DJ. Pharmacological mechanisms of benzodiazepine withdrawal. <i>J Psychiatr Res</i>. 1990;24 (Suppl 2):105-110. doi:10.1016/0022-3956(90)90041-n<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/1980689/pubmed" id="1980689" target="_blank">1980689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2905804">
<a name="2905804"></a>O'Boyle CA. Benzodiazepine-induced amnesia and anaesthetic practice: a review. <i>Psychopharmacol Ser</i>. 1988;6:146-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/2905804/pubmed" id="2905804" target="_blank">2905804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OConnor.2019">
<a name="OConnor.2019"></a>O'Connor FG, Casa DJ. Exertional heat illness in adolescents and adults: Management and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18073360">
<a name="18073360"></a>Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. <i>JAMA.</i> 2007;298(22):2644-2653.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18073360/pubmed" id="18073360" target="_blank">18073360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9845">
<a name="9845"></a>Pandit SK, Heisterkamp DV, Cohen PJ. Further studies of the anti-recall effect of lorazepam: a dose--time--effect relationship. <i>Anesthesiology</i>. 1976;45(5):495-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/9845/pubmed" id="9845" target="_blank">9845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16143486">
<a name="16143486"></a>Papini O, da Cunha SP, da Silva Mathes Ado C, et al. Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. <i>J Pharm Biomed Anal</i>. 2006;40(2):397-403. doi:10.1016/j.jpba.2005.07.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/16143486/pubmed" id="16143486" target="_blank">16143486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park TW. Benzodiazepine use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8700792">
<a name="8700792"></a>Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. <i>Pharmacotherapy</i>. 1996;16(1):49-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/8700792/pubmed" id="8700792" target="_blank">8700792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6123337">
<a name="6123337"></a>Peters CG, Brunton JT. Comparative study of lorazepam and trimeprazine for oral premedication in paediatric anaesthesia. <i>Br J Anaesth</i>. 1982;54(6):623-628.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6123337/pubmed" id="6123337" target="_blank">6123337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15961964">
<a name="15961964"></a>Pietras CJ, Lieving LM, Cherek DR, Lane SD, Tcheremissine OV, Nouvion S. Acute effects of lorazepam on laboratory measures of aggressive and escape responses of adult male parolees. <i>Behav Pharmacol</i>. 2005;16(4):243-51. doi:10.1097/01.fbp.0000170910.53415.77<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15961964/pubmed" id="15961964" target="_blank">15961964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28259732">
<a name="28259732"></a>Radojčić MR, El Marroun H, Miljković B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. <i>Neurotoxicol Teratol.</i> 2017;61:58-65. doi:10.1016/j.ntt.2017.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/28259732/pubmed" id="28259732" target="_blank">28259732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29723722">
<a name="29723722"></a>Reddy MSS, Achary U, Harbishettar V, Sivakumar PT, Varghese M. Paradoxical reaction to benzodiazepines in elderly - Case series. <i>Asian J Psychiatr</i>. 2018;35:8-10. doi:10.1016/j.ajp.2018.04.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/29723722/pubmed" id="29723722" target="_blank">29723722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32536331">
<a name="32536331"></a>Richardson JK, Eckner JT, Kim H, Ashton-Miller JA. A clinical method of evaluating simple reaction time and reaction accuracy is sensitive to a single dose of lorazepam. <i>J Psychopharmacol</i>. 2020;34(8):920-925. doi:10.1177/0269881120915409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/32536331/pubmed" id="32536331" target="_blank">32536331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19969591">
<a name="19969591"></a>Rosebush PI, Mazurek MF. Catatonia and its treatment. <i>Schizophr Bull.</i> 2010;36(2):239-242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/19969591/pubmed" id="19969591" target="_blank">19969591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6151849">
<a name="6151849"></a>Roth T, Roehrs T, Wittig R, Zorick F. Benzodiazepines and memory. <i>Br J Clin Pharmacol</i>. 1984;18 Suppl 1(Suppl 1):45S-49S. doi:10.1111/j.1365-2125.1984.tb02581.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6151849/pubmed" id="6151849" target="_blank">6151849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roy-Byrne.2019">
<a name="Roy-Byrne.2019"></a>Roy-Byrne PP. Management of psychiatric disorders in patients with cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18949456">
<a name="18949456"></a>Rozendaal FW, Spronk PE, Snellen FF, et al; UltiSAFE investigators. Remifentanil-propofol analgo-sedation shortens duration of ventilation and length of ICU stay compared to a conventional regimen: a centre randomised, cross-over, open-label study in the Netherlands. <i>Intensive Care Med</i>. 2009;35(2):291-298. doi: 10.1007/s00134-008-1328-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18949456/pubmed" id="18949456" target="_blank">18949456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29143367">
<a name="29143367"></a>Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. <i>Int J Geriatr Psychiatry</i>. 2018;33(4):583-590. doi: 10.1002/gps.4821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/29143367/pubmed" id="29143367" target="_blank">29143367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24407777">
<a name="24407777"></a>Sachdeva A, Chandra M, Deshpande SN. A comparative study of fixed tapering dose regimen versus symptom-triggered regimen of lorazepam for alcohol detoxification. <i>Alcohol Alcohol</i>. 2014;49(3):287-291. doi: 10.1093/alcalc/agt181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/24407777/pubmed" id="24407777" target="_blank">24407777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sansevere.1">
<a name="Sansevere.1"></a>Sansevere AJ, Bergin AM. Neonatal seizures. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Lippincott Williams &amp; Wilkins; 2022:chap. 56.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.2019">
<a name="Schachter.2019"></a>Schachter SC. Antiseizure medications: Mechanism of action, pharmacology, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6120058">
<a name="6120058"></a>Scharf MB, Kales A, Bixler EO, Jacoby JA, Schweitzer PK. Lorazepam-efficacy, side effects, and rebound phenomena. <i>Clin Pharmacol Ther</i>. 1982;31(2):175-179. doi:10.1038/clpt.1982.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6120058/pubmed" id="6120058" target="_blank">6120058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3698460">
<a name="3698460"></a>Shader RI, Dreyfuss D, Gerrein JR, Harmatz JS, Allison SJ, Greenblatt DJ. Sedative effects and impaired learning and recall after single oral doses of lorazepam. <i>Clin Pharmacol Ther</i>. 1986;39(5):526-529. doi:10.1038/clpt.1986.90<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/3698460/pubmed" id="3698460" target="_blank">3698460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shih.2019">
<a name="Shih.2019"></a>Shih G, Wallace R. First-trimester pregnancy termination: Uterine aspiration. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3661967">
<a name="3661967"></a>Short TG, Forrest P, Galletly DC. Paradoxical reactions to benzodiazepines--a genetically determined phenomenon? <i>Anaesth Intensive Care</i>. 1987;15(3):330-331. doi:10.1177/0310057X8701500314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/3661967/pubmed" id="3661967" target="_blank">3661967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SPS.2020">
<a name="SPS.2020"></a>Society for Pediatric Sedation (SPS). FDA advisory on anesthesia and sedation medication in children. Society for Pediatric Sedation website. Accessed April 2021. https://www.pedsedation.org/resources/quality-safety/fda-advisory/#:~:text=In%20December%202016%2C%20the%20FDA,(http%3A%2F%2Fwww.fda.
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solanki.1">
<a name="Solanki.1"></a>Solanki DI, Gohil JR, Patel AP. Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. <i>J Clin Neonatol</i>. 2015;4:232-236.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28006997">
<a name="28006997"></a>Soyka M, Kranzler HR, Hesselbrock V, Kasper S, Mutschler J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Substance Use Disorders. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. <i>World J Biol Psychiatry</i>. 2017;18(2):86-119. doi: 10.1080/15622975.2016.1246752.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/28006997/pubmed" id="28006997" target="_blank">28006997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.2019">
<a name="Stein.2019"></a>Stein MB. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15762814">
<a name="15762814"></a>Stewart SA. The effects of benzodiazepines on cognition. <i>J Clin Psychiatry</i>. 2005;66(suppl 2):9-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15762814/pubmed" id="15762814" target="_blank">15762814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stolbach.2019">
<a name="Stolbach.2019"></a>Stolbach A, Hoffman RS. Opioid withdrawal in the emergency setting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.1">
<a name="Stroup.1"></a>Stroup TS. Schizophrenia in adults: Maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4041315">
<a name="4041315"></a>Summerfield RJ, Nielsen MS. Excretion of lorazepam into breast milk. <i>Br J Anaesth</i>. 1985;57(10):1042-1043. doi:10.1093/bja/57.10.1042-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/4041315/pubmed" id="4041315" target="_blank">4041315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36520439">
<a name="36520439"></a>Sundbakk LM, Gran JM, Wood ME, Handal M, Skurtveit S, Nordeng H. Association of prenatal exposure to benzodiazepines and Z-hypnotics with risk of attention-deficit/hyperactivity disorder in childhood.<i> JAMA Netw Open</i>. 2022;5(12):e2246889. doi:10.1001/jamanetworkopen.2022.46889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/36520439/pubmed" id="36520439" target="_blank">36520439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15685515">
<a name="15685515"></a>Swart EL, de Jongh J, Zuideveld KP, Danhof M, Thijs LG, Strack van Schijndel RJ. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration.<i> Am J Kidney Dis</i>. 2005;45(2):360-371. doi:10.1053/j.ajkd.2004.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15685515/pubmed" id="15685515" target="_blank">15685515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15791890">
<a name="15791890"></a>Swartz R, Longwell P. Treatment of vertigo. <i>Am Fam Physician</i>. 2005;71(6):1115-1122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15791890/pubmed" id="15791890" target="_blank">15791890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Swinson.2019">
<a name="Swinson.2019"></a>Swinson R, McCabe RE. Pharmacotherapy for specific phobia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35909254">
<a name="35909254"></a>Szpunar MJ, Freeman MP, Kobylski LA, et al. Risk of major malformations in infants after first-trimester exposure to benzodiazepines: results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. <i>Depress Anxiety</i>. 2022;39(12):751-759. doi:10.1002/da.23280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/35909254/pubmed" id="35909254" target="_blank">35909254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21353710">
<a name="21353710"></a>Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. <i>Trends Neurosci</i>. 2011;34(4):188-197. doi:10.1016/j.tins.2011.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/21353710/pubmed" id="21353710" target="_blank">21353710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30632868">
<a name="30632868"></a>Thibaut F, Chagraoui A, Buckley L, et al. WFSBP and IAWMH guidelines for the treatment of alcohol use disorders in pregnant women. <i>World J Biol</i>
<i>Psychiatry</i>. 2019;20(1):17-50. doi:10.1080/15622975.2018.1510185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/30632868/pubmed" id="30632868" target="_blank">30632868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tietze.2019">
<a name="Tietze.2019"></a>Tietze KJ, Fuchs B. Sedative-analgesic medications in critically ill adults: Properties, dose regimens, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30891943">
<a name="30891943"></a>Tinker SC, Reefhuis J, Bitsko RH, et al; National Birth Defects Prevention Study. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. <i>Birth Defects Res</i>. 2019;111(10):613-620. doi:10.1002/bdr2.1497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/30891943/pubmed" id="30891943" target="_blank">30891943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30459031">
<a name="30459031"></a>Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. <i>Handb Clin Neurol</i>. 2018;157:663-675. doi: 10.1016/B978-0-444-64074-1.00039-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/30459031/pubmed" id="30459031" target="_blank">30459031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20979709">
<a name="20979709"></a>Tsai MC, Huang TL. Severe neuroleptic malignant syndrome: successful treatment with high-dose lorazepam and diazepam: a case report. <i>Chang Gung Med J</i>. 2010;33(5):576-580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/20979709/pubmed" id="20979709" target="_blank">20979709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10580363">
<a name="10580363"></a>Tsuda M, Shimizu N, Suzuki T. Contribution of glutamate receptors to benzodiazepine withdrawal signs. <i>Jpn J Pharmacol</i>. 1999;81(1):1-6. doi:10.1254/jjp.81.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/10580363/pubmed" id="10580363" target="_blank">10580363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2525581">
<a name="2525581"></a>Turkington D, Gill P. Mania induced by lorazepam withdrawal: a report of two cases. <i>J Affect Disord</i>. 1989;17(1):93-95. doi:10.1016/0165-0327(89)90028-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/2525581/pubmed" id="2525581" target="_blank">2525581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADOD.1">
<a name="VADOD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress reaction. <a href="https://www.healthquality.va.gov/guidelines/mh/ptsd/" target="_blank">https://www.healthquality.va.gov/guidelines/mh/ptsd/</a>. Updated 2017. Accessed September 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADOD.2">
<a name="VADOD.2"></a>US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. <a href="https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf</a>. Published August 2021. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11314681">
<a name="11314681"></a>van Laar M, Volkerts E, Verbaten M. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. <i>Psychopharmacology (Berl)</i>. 2001;154(2):189-197. doi:10.1007/s002130000633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/11314681/pubmed" id="11314681" target="_blank">11314681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15266351">
<a name="15266351"></a>Van Sickle BJ, Xiang K, Tietz EI. Transient plasticity of hippocampal CA1 neuron glutamate receptors contributes to benzodiazepine withdrawal-anxiety. <i>Neuropsychopharmacology</i>. 2004;29(11):1994-2006. doi:10.1038/sj.npp.1300531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15266351/pubmed" id="15266351" target="_blank">15266351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22216526">
<a name="22216526"></a>Verbeeck R, Tjandramaga TB, Verberckmoes R, De Schepper PJ. Biotransformation and excretion of lorazepam in patients with chronic renal failure. <i>Br J Clin Pharmacol</i>. 1976;3(6):1033-1039. doi:10.1111/j.1365-2125.1976.tb00354.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22216526/pubmed" id="22216526" target="_blank">22216526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22536226">
<a name="22536226"></a>Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective gaba(a) receptor modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:1-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22536226/pubmed" id="22536226" target="_blank">22536226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-vonGunten.2019">
<a name="vonGunten.2019"></a>von Gunten C, Buckholz G. Palliative care: Overview of cough, stridor, and hemoptysis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27824534">
<a name="27824534"></a>Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: Preventing, recognizing, and treating it. <i>Cleve Clin J Med</i>. 2016;83(11):810-817. doi:10.3949/ccjm.83a.15129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/27824534/pubmed" id="27824534" target="_blank">27824534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35367514">
<a name="35367514"></a>Wang X, Zhang T, Ekheden I, et al. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: a systematic review. <i>Neurosci Biobehav Rev</i>. 2022;137:104647. doi:10.1016/j.neubiorev.2022.104647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/35367514/pubmed" id="35367514" target="_blank">35367514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29325237">
<a name="29325237"></a>Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. <i>Prim Care Companion CNS Disord.</i> 2018;20(1). pii: 17r02185. doi:10.4088/PCC.17r02185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/29325237/pubmed" id="29325237" target="_blank">29325237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11697755">
<a name="11697755"></a>Wermeling DP, Miller JL, Archer SM, Manaligod JM, Rudy AC. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. <i>J Clin Pharmacol</i>. 2001;41(11):1225-1231. doi:10.1177/00912700122012779<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/11697755/pubmed" id="11697755" target="_blank">11697755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6113019">
<a name="6113019"></a>Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. <i>Br Med J (Clin Res Ed)</i>. 1981;282(6270):1106-1108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6113019/pubmed" id="6113019" target="_blank">6113019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29605483">
<a name="29605483"></a>Wightman RS, Nelson LS, Lee JD, Fox LM, Smith SW. Severe opioid withdrawal precipitated by Vivitrol. <i>Am J Emerg Med</i>. 2018;36(6):1128.e1-1128.e2. doi:10.1016/j.ajem.2018.03.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/29605483/pubmed" id="29605483" target="_blank">29605483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wijdicks.2019">
<a name="Wijdicks.2019"></a>Wijdicks EFM. Neuroleptic malignant syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17894421">
<a name="17894421"></a>Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. <i>Pharmacoepidemiol Drug Saf.</i> 2007;16(11):1203-1210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/17894421/pubmed" id="17894421" target="_blank">17894421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10991709">
<a name="10991709"></a>Wilson KC, Reardon C, Farber HW. Propylene glycol toxicity in a patient receiving intravenous diazepam. <i>N Engl J Med</i>. 2000;343(11):815. doi:10.1056/nejm200009143431115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/10991709/pubmed" id="10991709" target="_blank">10991709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31271339">
<a name="31271339"></a>Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. <i>J Psychopharmacol</i>. 2019;33(8):923-947. doi:10.1177/0269881119855343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/31271339/pubmed" id="31271339" target="_blank">31271339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28297728">
<a name="28297728"></a>Wodarz N, Krampe-Scheidler A, Christ M, et al. Evidence-based guidelines for the pharmacological management of acute methamphetamine-related disorders and toxicity. <i>Pharmacopsychiatry</i>. 2017;50(3):87-95. doi: 10.1055/s-0042-123752.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/28297728/pubmed" id="28297728" target="_blank">28297728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Guidelines for the identification and management of substance use and substance use disorders in pregnancy. Geneva: World Health Organization. 2014. Available at <a href="https://www.ncbi.nlm.nih.gov/books/NBK200701/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK200701/</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18657015">
<a name="18657015"></a>Yahwak JA, Riker RR, Fraser GL, Subak-Sharpe S. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. <i>Pharmacotherapy</i>. 2008;28(8):984-991.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18657015/pubmed" id="18657015" target="_blank">18657015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14524641">
<a name="14524641"></a>Yaucher NE, Fish JT, Smith HW, Wells JA. Propylene glycol-associated renal toxicity from lorazepam infusion. <i>Pharmacotherapy</i>. 2003;23(9):1094-1099. doi:10.1592/phco.23.10.1094.32762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/14524641/pubmed" id="14524641" target="_blank">14524641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15283543">
<a name="15283543"></a>Ziegenbein M, Kropp S. Lorazepam-induced prolongation of the QT interval in a patient with schizoaffective disorder and complete AV block. <i>Can J Psychiatry</i>. 2004;49(6):414. doi:10.1177/070674370404900619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/15283543/pubmed" id="15283543" target="_blank">15283543</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12565 Version 708.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
